

## TUBERCULOSIS

# Current evidence on diagnostic accuracy of commercially based nucleic acid amplification tests for the diagnosis of pulmonary tuberculosis

S Greco, E Girardi, A Navarra, C Saltini



Thorax 2006;61:783–790. doi: 10.1136/thx.2005.054908

See end of article for authors' affiliations

Correspondence to:  
Dr S Greco, Dipartimento  
di Malattie Polmonari,  
Azienda Ospedaliera San  
Camillo-Forlanini, 00151  
Rome, Italy; stgreco@  
scamilloforlanini.rm.it

Received 26 October 2005  
Accepted 18 May 2006  
Published Online First  
31 May 2006

**Background:** Even though commercial nucleic acid amplification tests (NAATs) have become the most frequently used molecular tests for laboratory diagnosis of pulmonary tuberculosis (TB), published studies report variable estimates of their diagnostic accuracy. We analysed the accuracy of commercial NAATs for the diagnosis of pulmonary TB in smear positive and smear negative respiratory samples using culture as a reference standard.

**Methods:** English language studies reporting data sufficient for calculating sensitivity and specificity of commercial NAATs on smear positive and/or smear negative respiratory samples were included. Meta-regression was used to analyse associations with reference test quality, the prevalence of TB, sample and test type. Predictive values for different levels of pre-test probability were quantified using Bayes' approach.

**Results:** Sixty three journal articles published between 1995 and 2004 met the inclusion criteria. Pooled sensitivity and specificity were 0.96 and 0.85 among smear positive samples and 0.66 and 0.98 among smear negative samples. The number of culture media used as reference test, the inclusion of bronchial samples, and the TB prevalence were found to influence the reported accuracy. The test type had no effect on the diagnostic odds ratio but seemed to be correlated with sensitivity or specificity, probably via a threshold effect.

**Conclusions:** Commercial NAATs can be confidently used to exclude TB in patients with smear positive samples in which environmental mycobacteria infection is suspected and to confirm TB in a proportion of smear negative cases. The methodological characteristics of primary studies have a considerable effect on the reported diagnostic accuracy.

In spite of their theoretical ability to detect even a single mycobacterial cell, nucleic acid amplification tests (NAATs) are not sufficiently reliable to replace conventional diagnostic methods for pulmonary tuberculosis (TB). Both inherent test characteristics and errors in testing procedures may account for their inaccuracy.<sup>1</sup> As for microscopy and culture, the key factor in determining NAAT false negatives is the density of mycobacteria in the specimen, since it can result in the absence of organisms in the small volumes sampled for the test. Furthermore, the presence in respiratory secretions of enzymes capable of inhibiting amplification reactions accounts for an additional 3–25% of false negative results.<sup>2</sup> On the other hand, false positive results arise most often from contamination of negative samples with either organisms or target DNA from samples containing large numbers of mycobacteria or from amplicons contaminating the laboratory room.<sup>2,3</sup>

To overcome these problems, automated commercial systems were developed which were made more robust by the use of standardised procedures and reagents for sample processing, amplification, and detection. These procedures, which allow different steps of the process to take place in a single sealed tube, were intended to reduce the risk of contamination. At the same time, the use of larger sample volumes or the introduction of internal amplification controls to detect inhibitors was adopted to cut down the rate of false negative results.

Notwithstanding these precautionary measures, published studies show a considerable heterogeneity in the results obtained with commercial NAATs. The US Centers for Disease Control (CDC) recommend that commercial NAATs

be used with microscopy to improve diagnostic certainty (pending culture results and/or patient's response to treatment) and that clinicians should rely on their clinical judgement in the interpretation of results. According to the CDC, the diagnosis of pulmonary TB can be presumed in smear positive (acid-fast bacilli (AFB)+) patients with a positive NAAT result and in smear negative (AFB–) patients with two subsequent positive NAAT results. Environmental mycobacterial disease can be hypothesised when a negative NAAT result is obtained from an AFB+ and inhibitor-free sample while, as about 20% of TB cases can be attributed to infection by AFB– patients,<sup>4</sup> two negative NAAT results from two separate AFB– samples are needed to exclude contagiousness.<sup>5</sup>

Two previous meta-analyses on the accuracy of NAATs for the diagnosis of pulmonary TB, analysing mostly home grown polymerase chain reaction (PCR) based tests, found a substantial variability in both sensitivity and specificity due to the different threshold set by each investigator and to differences in study design and quality.<sup>6,7</sup> To our knowledge, the diagnostic accuracy of commercial NAATs separately on both AFB+ and AFB– respiratory samples has never been systematically reviewed. This study was undertaken to assess the performance of NAATs in the context of a careful analysis of the impact of the type of test as well as of the methodological and clinical characteristics of published studies on the accuracy estimates.

**Abbreviations:** AFB, acid-fast bacilli; DOR, diagnostic odds ratio; MTB, *Mycobacterium tuberculosis*; NAAT, nucleic acid amplification test; TB, tuberculosis

## METHODS

We searched Medline to 1 July 2005 and Embase to 1 March 2005 using a search strategy designed to identify studies evaluating the use of commercial NAATs for the diagnosis of pulmonary TB. The titles and abstracts of the identified citations were screened and the references listed in the retrieved articles were scrutinised, considering any citation that did not obviously fail the inclusion criteria.

After a preliminary analysis of a sample of articles, studies considered eligible for inclusion in our meta-analysis were those that:

- (1) examined the diagnostic performance of commercial NAATs on respiratory samples (<5% of non-respiratory samples were tolerated);
- (2) used *Mycobacterium tuberculosis* (MTB) culture of the same sample as the reference standard for the diagnosis of pulmonary TB;
- (3) reported primary data sufficient for separately calculating both sensitivity and specificity in AFB+ and/or AFB– specimens; and
- (4) were written in English.

Articles were excluded from the meta-analysis for the following reasons:

- (1) reporting sensitivity and specificity “revised” by means of discrepant analysis as the only study results; in the case of studies which retested the samples on the basis of discrepant analysis, only the initial “unrevised” results were considered;
- (2) possible duplicate publication: when an author or research group published more than one study, the existence of overlapping study populations was ascertained by checking sample recruitment sites and/or periods or, if these were not available, contacting authors for clarification. If this was not provided, only the article reporting the largest number of samples was included;
- (3) application of commercial NAATs on gastric aspirates (>5% of total study sample); and
- (4) analysis of previous versions of commercial NAATs.

Two investigators independently evaluated studies for inclusion and abstracted relevant data. Disagreements were reconciled by consensus.

## Data extraction and quality assessment

Data were abstracted using two separate data sheets, one for AFB+ and one for AFB– samples. Information recorded were descriptive data (author name, journal, publication year), type of respiratory sample, prevalence of MTB culture positive samples, testing procedures for commercial NAATs, culture and AFB staining, and commercial NAAT sensitivity and specificity.

According to the established methodological standards for evaluation of diagnostic tests,<sup>8</sup> four aspects of study quality were examined: cohort assembly (population of recruitment, method of sample selection, data collection modality), technical quality of reference test (the use of at least two different culture media was considered a more reliable reference test), blinding, and study population features (clinical/demographic characteristics, pulmonary TB severity, and other diagnoses in subjects without pulmonary TB). The original studies in which data were collected (or primary studies) were classified according to whether each characteristic was present, absent, or unknown. In five multicentre studies the participating laboratories used different AFB staining and/or culture procedures: these items were scored as unknown. Three studies included a separate

description of a subgroup of patients on antituberculous therapy: these data were not included in our analysis and the studies were scored as not including patients under treatment.

## Statistical analysis

All statistical analyses were separately performed for AFB+ and AFB– samples. For each study we classified the commercial NAAT results as true positives (TP), false negatives (FN), false positives (FP), and true negatives (TN) as determined by comparison with MTB culture results. We then calculated the true positive rate ( $TPR = TP / (TP + FN)$  = sensitivity), the true negative rate ( $TNR = TN / (FP + TN)$  = specificity), their odds ( $oddsTPR = TPR / (1 - TPR)$  and  $oddsTNR = TNR / (1 - TNR)$ ), and the diagnostic odds ratio (DOR)—that is, the ratio of the odds of a positive NAAT result among MTB culture positive samples compared with MTB culture negative samples ( $DOR = oddsTPR / oddsFP$  rate). Thus, DOR values of >1 indicate good test performance while DOR values of <1 indicate a test more frequently positive on control subjects (DOR = 1 means that the test had no discriminating ability).

The potential problems in odds calculations associated with sensitivities and/or specificities of 100% were solved by adding 0.5 to zero values.<sup>9</sup> In articles where two or more different commercial NAATs were analysed on the same samples, both extraction of data and calculation of accuracy measures were performed by considering them as separate studies.


To delineate the impact of study characteristics on diagnostic accuracy estimates, we fitted a multivariate random effect regression model using DOR as the dependent variable and study characteristics as explanatory variables (“Metareg”, Stata 8). Since each commercial NAAT fixes a well defined numerical value as the criterion for positivity, we took into account the threshold differences between studies by simply adding the test type as covariate in the regression model.<sup>9</sup>

However, clinical interpretation of DOR is not easy as the same values can relate to different combinations of sensitivity and specificity.<sup>10</sup> The use of fixed thresholds allowed us to explore the impact of the study characteristics (including the different thresholds chosen) on sensitivity and specificity separately. We therefore constructed two further regression models using, as dependent variables,  $oddsTPR$  and  $oddsTNR$ , respectively. For all the models the dependent variables were included after logarithmic transformation.

As explanatory variables we added the clinical and methodological characteristics of the primary studies to the regression models. Since unreported items can reflect true methodological flaws or poor reporting of a methodologically sound study, we only included variables with a percentage of unreported items of <15%. As it is known that sensitivity and specificity vary with disease prevalence when an imperfect standard is used to evaluate a test, we added to the models the proportion of MTB culture positive samples (among AFB+ or AFB– samples) as a proxy of the true prevalence of pulmonary TB.<sup>11, 12</sup>

The within-study variance was considered by taking weights equal to the inverse of the variance of the appropriate proportions; the between-study variance was estimated using the restricted maximum likelihood estimate (REML).<sup>13</sup>

We assessed the possibility of publication bias by evaluating a funnel plot for asymmetry, Begg’s adjusted rank correlation test and Egger’s regression asymmetry test (“Metabias”, Stata 8). Finally, we applied Bayes’ theorem to assess the changes in probability of pulmonary TB determined by the use of commercial NAATs.



**Figure 1** Individual study estimates of sensitivity and specificity of commercial nucleic acid amplification tests (NAATs) for the diagnosis of pulmonary TB on (A) AFB+ samples and (B) AFB– samples. Pooled values were calculated using a random effect model. Error bars represent 95% confidence intervals. Five articles on AFB+ samples and eight articles on AFB– samples analysing two commercial NAATs each are cited twice.

RESULTS

Study description and synthesis

The study selection process, which is reported in full in the online Appendix available at <http://www.thoraxjnl.com/supplemental>, led to the inclusion of 63 journal articles published between 1995 and 2004.<sup>14–76</sup> Since eight articles analysed two different commercial NAATs, a total of 71 studies were available for analysis. The commercial NAATs evaluated were: Roche Amplicor MTB (n = 25 studies), its entirely automated version, Cobas Amplicor MTB (n = 10), E-MTD (n = 14), BDProbeTectET (n = 12), and LCx (n = 10). Overall, the 63 articles examined 51 160 samples, 5729 MTB culture positive and 45 431 MTB culture negative. The median number of samples per study was 410 (interquartile

range (IQR) 247–662), with a median pulmonary TB prevalence of 0.14 (IQR 0.07–0.3).

Fifty six articles analysed both sensitivity and specificity of commercial NAATs on AFB+ samples. They included 3848 MTB culture positive and 1535 MTB culture negative samples, with a median pulmonary TB prevalence of 0.77 (IQR 0.6–0.86). Five articles reviewed two commercial NAATs each, so 61 studies were available for analysis. As shown in fig 1A, sensitivity values were homogeneously higher (0.96, 95% CI 0.956 to 0.968) while specificity was lower and extremely variable (0.85, 95% CI 0.84 to 0.87).

The 60 articles examining the sensitivity and specificity of commercial NAATs on AFB– samples included 1704 MTB culture positive and 43 852 MTB culture negative samples

Table 1 Pooled values* (95% confidence intervals) of diagnostic odds ratio (DOR), sensitivity, and specificity of five commercial nucleic acid amplification tests (NAATs)							
Test	NAA method	AFB+			AFB–		
		DOR	Sensitivity	Specificity	DOR	Sensitivity	Specificity
Amplicor	PCR	117 (56 to 246)	0.96 (0.94 to 0.97)	0.83 (0.8 to 0.86)	77 (51 to 115)	0.61 (0.57 to 0.65)	0.97 (0.968 to 0.974)
Cobas Amplicor	PCR	99 (56 to 173)	0.96 (0.95 to 0.97)	0.74 (0.68 to 0.8)	220 (144 to 335)	0.64 (0.59 to 0.69)	0.993 (0.992 to 0.994)
BDP	SDA	181 (39 to 834)	0.98 (0.96 to 0.99)	0.89 (0.84 to 0.93)	96 (53 to 175)	0.71 (0.66 to 0.76)	0.97 (0.964 to 0.974)
E-MTD	TMA	314 (99 to 995)	0.97 (0.95 to 0.98)	0.96 (0.93 to 0.97)	157 (48 to 510)	0.76 (0.7 to 0.8)	0.97 (0.966 to 0.974)
LCx	LCR	42 (12 to 142)	0.96 (0.94 to 0.98)	0.71 (0.64 to 0.78)	71 (38 to 132)	0.57 (0.5 to 0.64)	0.98 (0.978 to 0.985)

PCR, polymerase chain reaction; SDA, strand displacement amplification; TMA, transcription mediated amplification; LCR, ligase chain reaction; DOR, diagnostic odds ratio.  
\*Random effect model.

**Table 2** Analysis of the methodological characteristics of the primary studies included in the meta-analysis

Characteristic	Number of studies (%)		
	All (n = 63)	AFB+ samples (n = 56)	AFB- samples (n = 60)
Type of respiratory specimen			
Sputum	8 (13)	6 (11)	8 (13)
Bronchial secretions	1 (2)	0	1 (2)
Mixed respiratory secretions	54 (86)	50 (89)	50 (83)
AFB method			
Fluorescence	45 (71)	43 (77)	42 (70)
Carbolfuchsin	7 (11)	3 (5)	7 (12)
Unreported	11 (17)	10 (18)	11 (18)
Quality of reference test			
At least two culture media	41 (65)	38 (68)	38 (63)
One culture media	15 (24)	11 (20)	15 (25)
Unreported	7 (11)	7 (13)	7 (12)
Commercial NAAT used			
Amplicor	25	22	22
Cobas Amplicor	10	8	10
BDProbeTecET	12	10	12
E-MTD	14	12	14
LCx	10	9	10
Population of recruitment			
MTB culture or suspected PTB	29 (46)	27 (48)	27 (45)
High PTB suspicion	3 (5)	3 (5)	3 (5)
Suspected PTB or treatment monitoring	10 (16)	9 (16)	10 (17)
Other	5 (8)	4 (7)	4 (7)
Screening	3 (5)	3 (5)	3 (5)
Unreported	13 (21)	10 (18)	13 (22)
On anti-TB treatment			
Yes	31 (49)	29 (52)	31 (52)
No	15 (24)	12 (21)	14 (23)
Unreported	20 (32)	15 (27)	18 (30)
Method of sample selection			
Consecutive or random selection	20 (32)	17 (30)	20 (33)
Case control	5 (8)	5 (9)	4 (7)
Consecutive/case control	1 (2)	1 (2)	1 (2)
Unreported	37 (59)	33 (59)	35 (58)
Data collection modality			
Prospective	8 (13)	7 (13)	8 (13)
Retrospective	5 (8)	4 (7)	5 (8)
Prospective/retrospective	2 (3)	2 (4)	2 (3)
Unreported	48 (76)	43 (77)	45 (75)
Independence of observation			
Any blinding	10 (16)	7 (13)	9 (15)
Unreported	53 (84)	49 (88)	51 (85)
Clinical/demographic characteristics			
Reported	3 (5)	3 (5)	3 (5)
Unreported	60 (95)	53 (95)	57 (95)
Distribution of TB severity			
Results of quantitative culture reported	7 (11)	7 (13)	7 (12)
Unreported	56 (89)	49 (88)	53 (88)
Other diagnoses in the control group			
Reported	1 (2)	1 (2)	1 (2)
Unreported	62 (98)	55 (98)	59 (98)

PTB, pulmonary tuberculosis.

(median pulmonary TB prevalence 0.042, IQR 0.02–0.1). Eight articles reviewed two commercial NAATs each, bringing the total number of studies up to 68. Inspection of the forest plot in fig 1B indicates a high specificity but a clear heterogeneity in sensitivity values. Pooled sensitivity and specificity were 0.66 (95% CI 0.63 to 0.68) and 0.98 (95% CI 0.978 to 0.981), respectively. Pooled values of DOR, sensitivity, and specificity for each test type as well as their respective nucleic acid amplification techniques are reported in table 1.

Analysis of clinical and methodological characteristics of the primary studies (table 2) showed that many studies did not comply with the published guidelines for conducting and reporting diagnostic test evaluation. With regard to MTB culture (most frequently Lowenstein-Jensen (68%) and Bactec 12B (52%)), we found that 11% of primary studies did not provide any description of the reference test used to assess pulmonary TB diagnosis, while approximately one quarter used only one culture medium. Even if more than

half of the studies declared the enrollment of patients with suspected pulmonary TB, they often included samples from patients on antituberculous treatment. The clinical spectrum of both pulmonary TB and comparative groups was rarely given and only nine primary studies applied either single or double blinding for test interpretation.

### Effect of study characteristics on diagnostic accuracy of commercial NAATs

The characteristics of the studies analysing AFB+ and AFB- samples are shown in the last two columns of table 2. Those included in the meta-regression models as potential sources of heterogeneity were quality of reference test, specimen type, commercial NAAT type, and pulmonary TB prevalence. In table 3 the resulting parameter estimates of these variables are presented as relative odds. Relative odds indicate the diagnostic performance of commercial NAATs in studies with



**Table 3** Effect of study characteristics on estimates of diagnostic odds ratio (DOR), sensitivity, and specificity, as determined by meta-regression analysis

Study characteristic	Relative DOR (95% CI)	p value	Relative oddsTPR (95% CI)	p value	Relative oddsTNR (95% CI)	p value
<i>AFB+ samples</i>						
At least 2 culture media used	8.13 (2.59 to 25.49)	0.000	1.64 (0.90 to 3.00)	0.106	2.82 (1.04 to 7.68)	0.042
PTB prevalence	0.09 (0.01 to 1.72)	0.111	0.61 (0.12 to 3.10)	0.551	0.08 (0.01 to 0.96)	0.046
Inclusion of bronchial samples	6.67 (1.36 to 32.63)	0.019	0.66 (0.22 to 1.97)	0.495	5.40 (1.55 to 18.79)	0.008
Amplicor	0.87 (0.23 to 3.32)	0.838	1.08 (0.56 to 2.09)	0.812	0.54 (0.17 to 1.73)	0.297
Cobas Amplicor	0.52 (0.11 to 2.43)	0.405	1.22 (0.56 to 2.6)	0.620	0.43 (0.11 to 1.72)	0.234
BDProbeTecET	0.84 (0.17 to 4.06)	0.831	2.20 (0.91 to 5.30)	0.080	0.57 (0.15 to 2.25)	0.424
LCx	0.24 (0.05 to 1.07)	0.062	1.06 (0.48 to 2.32)	0.893	0.20 (0.05 to 0.75)	0.017
<i>AFB- samples</i>						
At least 2 culture media used	2.26 (1.13 to 4.53)	0.021	0.97 (0.65 to 1.47)	0.895	2.77 (1.63 to 4.73)	0.000
PTB prevalence	0.02 (0.00 to 0.66)	0.028	0.45 (0.10 to 2.16)	0.322	0.01 (0.00 to 0.23)	0.003
Inclusion of bronchial samples	1.79 (0.68 to 4.70)	0.238	0.63 (0.35 to 1.16)	0.138	2.58 (1.24 to 5.37)	0.011
Amplicor	0.91 (0.36 to 2.27)	0.839	0.47 (0.28 to 0.79)	0.005	1.90 (0.93 to 3.89)	0.081
Cobas Amplicor	1.67 (0.58 to 4.82)	0.342	0.63 (0.35 to 1.13)	0.119	2.48 (1.07 to 5.76)	0.034
BDProbeTecET	0.89 (0.34 to 2.32)	0.815	0.79 (0.45 to 1.38)	0.404	1.18 (0.56 to 2.48)	0.670
LCx	0.61 (0.22 to 1.68)	0.338	0.44 (0.24 to 0.81)	0.008	1.20 (0.55 to 2.59)	0.649

Results are expressed as relative odds and 95% confidence intervals.  
DOR, diagnostic odds ratio; TPR, sensitivity; TNR, specificity; PTB, pulmonary tuberculosis.  
The coding used in multiple regression analysis was: sample type, inclusion of bronchial specimens = 1, sputum only = 0; MTB culture, at least two media used = 1, no information on culture media used = 1 (not reported in the table), one culture medium used = 0; cNAAT type, Amplicor = 1, Cobas Amplicor = 1, BDP = 1, LCx = 1, E-MTD = 0.

that characteristic, relative to their performance in studies without that characteristic.


For AFB+ samples, studies using at least two MTB culture media and those including bronchial specimens yielded DOR values approximately eight times higher than those using one culture media and six times higher than those analysing sputum specimens only, mainly due to an effect on oddsTNR. OddsTNR values were inversely correlated with the prevalence of pulmonary TB and were significantly lower in studies of the LCx test than in those analysing E-MTD. For AFB- samples, the relative DOR of studies using at least two MTB culture media were more than twice as high as those of studies using only one medium, mainly due to the increase in oddsTNR. The inclusion of bronchial specimens was also associated with increased oddsTNR values. In comparison with studies analysing E-MTD, those using LCx or Roche Amplicor MTB provided lower oddsTPR, while those using Cobas Amplicor MTB yielded higher oddsTNR. An inverse

correlation between the prevalence of pulmonary TB and both DOR and oddsTNR values was also found.

Evaluation of publication bias showed that the Egger's test was significant both for studies on AFB+ samples (regression coefficient 1.14,  $p = 0.011$ ) and for AFB- samples (regression coefficient 0.97  $p = 0.022$ ). Visual inspection of the two funnel plots also showed some asymmetry. Conversely, the Begg's test was not significant (see Appendix).

**Post-test probability of pulmonary TB**

Changes in the likelihood of pulmonary TB after performing the commercial NAATs are shown for all pre-test probabilities in fig 2A and B for AFB+ and AFB- samples. The top curves portray the positive predictive values—that is, the probabilities of pulmonary TB after obtaining a positive commercial NAAT result. The bottom curves represent the inverse of the negative predictive values—that is, the probabilities of pulmonary TB after a negative commercial NAAT result. For



**Figure 2** Predictive values of pulmonary TB after performing a commercial nucleic acid amplification test (NAAT) in (A) AFB+ samples and (B) AFB- samples. Post-test probabilities were calculated using pooled sensitivity and specificity values for each test type. Top curves represent positive predictive values, bottom curves represent 1 - negative predictive values.

example, using E-MTD on an AFB– sample from a patient in whom previous diagnostic information (history taking, clinical examination, imaging, etc) indicated a probability of pulmonary TB of about 30%, a negative result would reduce the likelihood of pulmonary TB to about 10% while a positive one would increase it to about 90%.

## DISCUSSION

Since commercial NAATs require fewer technical skills and a shorter assay time than the less expensive home grown tests, they have become the most frequently used molecular tests for laboratory diagnosis of pulmonary TB.<sup>77</sup> In this meta-analysis we calculated pooled estimates of their sensitivity and specificity (table 1), showed that their reported accuracy is influenced by primary study characteristics, and analysed to what degree or under what conditions they add information to the diagnostic work-up of pulmonary TB.

The reference test used for diagnosing pulmonary TB was shown to have the largest impact on accuracy, both for AFB+ and AFB– samples. Since the incorporation of one or more additional units of medium is known to reduce the false negative rates of culture,<sup>78</sup> it could, as a consequence, have determined an “artificial” improvement in commercial NAAT specificity that is estimated on samples classified by culture as MTB-free.

The small number of studies using liquid media as the only reference test did not allow us to evaluate the independent effect on accuracy of their higher MTB recovery rates compared with solid media.<sup>78</sup>

The imperfect sensitivity of culture could also explain the variation in the specificity (and the DOR) of commercial NAATs with the prevalence of TB. At a low prevalence, the number of samples containing MTB (but wrongly classified by culture as MTB-free) is in fact likely to be small and commercial NAAT (pseudo) false positives are likely to occur less frequently. However, at a high prevalence, the higher number of (pseudo) false positives reduces the specificity.<sup>12</sup>

The higher accuracy in studies including bronchial samples, already reported in a previous meta-analysis on PCR-based NAATs,<sup>6</sup> was mainly due to an increase in specificity. However, since the reported culture yield in bronchial samples varies from 12% to 87%,<sup>79–80</sup> it is difficult to explain these data on the basis of the proportional agreement of positive and negative results between the two tests. Studies focused on diagnostic performance of both culture and commercial NAATs on different bronchial samples may help to clarify this issue in the future.

Although only Amplicor (or Cobas Amplicor) and E-MTD are currently approved by the United States FDA for clinical use, the test type did not seem to explain the heterogeneity of DOR in meta-regression. Interestingly, studies evaluating E-MTD on AFB– samples yielded higher sensitivities and lower specificities than those using Roche Amplicor MTB or Cobas Amplicor MTB (table 3). The higher sensitivity of E-MTD, the only NAAT approved by the FDA for use on AFB– samples, could be due to kit features such as the use of ribosomal RNA as a target sequence (about 2000 copies in each MTB cell),<sup>81</sup> but our results suggest that E-MTD could use a lower positivity criterion than other commercial NAATs and the differences observed could be partly due to a “threshold effect”. The accuracy of E-MTD appeared to be higher than that of the recently withdrawn Abbott LCx, while no differences were seen with BDProbeTecET.

With respect to the diagnostic value of commercial NAATs in the evaluation of patients with suspected pulmonary TB, we observed that, because of their very high sensitivity on AFB+ samples, commercial NAATs can be confidently used to “rule out” pulmonary TB in AFB+ patients (fig 2A). Thus, particularly in settings where opportunistic infections are a

concern, a negative inhibitor-free commercial NAAT in patients with AFB+ smears and suggestive radiographic abnormalities should direct suspicion towards an environmental mycobacterial pulmonary disease.

The more limited gain in likelihood of pulmonary TB after a positive result on AFB+ samples (particularly for some commercial NAATs, see fig 2) seems to limit their use as confirmatory tests in these cases. The increased false positive rates of a number of studies may be related to the inclusion of samples from patients under treatment. These studies tried to correct the errors deriving from the enrollment of an inadequate study population by applying discrepant analysis, a statistical ploy that attempts to correct sensitivity and specificity of a “new” test (that is supposed to be more accurate than the reference standard it is compared with) by involving an additional more reliable test (clinical diagnosis of pulmonary TB). This procedure, by correcting the errors hidden among conflicting results of the “new” test and the standard and by disregarding concordant errors, leads to an overestimation of the accuracy of the test.<sup>82</sup> We therefore decided to include only “uncorrected” results, hence discussing the possible effects on accuracy of the presence of samples from treated patients. The unavailability of treatment data from 27% of primary papers prevented us from drawing conclusions by means of meta-regression. Nevertheless, the pooled specificities calculated on the subgroup of studies clearly stating the exclusion ( $n = 206$  samples) and inclusion ( $n = 707$  samples) of treated patients were 0.97 (95% CI 0.93 to 0.99) and 0.76 (95% CI 0.73 to 0.79), respectively, indicating that inclusion of treated patient samples was the main cause for reduced specificity in AFB+ samples.

In the case of a negative microscopy result, commercial NAATs are not sensitive enough to exclude the diagnosis of pulmonary TB and further diagnostic work-up remains mandatory in these patients. By contrast, their high specificity gives them the ability to “rule in” pulmonary TB in about two thirds of patients who will be recognised as MTB culture positive only 2–8 weeks later (fig 2B). Based on the degree of suspicion, the clinician is allowed to initiate treatment or, having already begun it, is made more comfortable to continue it. Furthermore, and with regard to the risk assessment of infectivity, because commercial NAATs have a higher sensitivity than microscopy, they could guide the decision as to which AFB– patients are to be segregated, especially in facilities where HIV infected or other immunocompromised individuals are managed.<sup>83</sup> However, this use is of limited value in patients already started on treatment as the numbers of viable mycobacteria in the sputum are known to dramatically fall in the first few days.<sup>84</sup>

This meta-analysis has limitations. Firstly, the sensitivity and specificity estimates of commercial NAATs are hindered by the poor quality of primary studies, a common problem in diagnostic meta-analyses. Furthermore, although the Egger’s test may reveal artifactual correlations between DOR and its variance regardless of publication bias,<sup>85–86</sup> the possibility that the studies included in our meta-analysis are a biased set cannot be ruled out. In spite of these drawbacks, we think that summary estimates of test performance are a more accurate guide for the physician than the results of any one of the primary studies.

Secondly, our decision to use the specimen as the unit of analysis could have affected accuracy because of the possible inclusion of multiple paucibacillary specimens from AFB– patients. Nevertheless, we speculated that the use of the patient as unit of analysis could have determined even wider variations in accuracy as the number of specimens per patient varied both within and between primary studies and repetitive testing is known to improve sensitivity.

Thirdly, we examined the accuracy of commercial NAATs in comparison with culture, without addressing the issue of microscopy-negative and culture-negative pulmonary TB cases diagnosed on clinical grounds only. During the systematic review of the literature we found only six studies and one FDA premarket approval application document confronting this problem.<sup>81–92</sup> Out of 69 specimens (52 patients), only seven provided at least one specimen that tested positive with commercial NAATs, corresponding to a pooled sensitivity of 10% (95% CI 4 to 20). Our estimates of sensitivity on AFB– samples are therefore probably inflated compared with what can be seen in the clinical setting.

Based on this systematic review, the clinical use of commercial NAATs should be limited to the exclusion of a diagnosis of TB in AFB+ patients with suspected non-tuberculous mycobacterial infection and to the confirmation of TB in a percentage of those providing AFB– samples. Further studies using rigorous methods—including careful control for treatment and use of single specimen per patient—would be highly desirable to appreciate better the operating characteristics of the commercial NAATs. Their accuracy on different bronchial specimens and on samples from patients with culture negative pulmonary TB are also important issues that remain to be addressed.



Full details of the study selection process are shown in the online Appendix available at <http://www.thoraxjnl.com/supplemental>.

#### Authors' affiliations

**S Greco**, Dipartimento di Malattie Polmonari, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy

**S Greco, C Saltini**, Dipartimento di Medicina Interna, Università di Roma "Tor Vergata", Rome, Italy

**E Girardi, A Navarra**, Dipartimento di Epidemiologia, INMI L Sallanzani-IRCCS, Rome, Italy

Competing interests: none declared

#### REFERENCES

- Noordhoek GT, Van Embden JDA, Kolk AHJ. Questionable reliability of the polymerase chain reaction in the detection of *Mycobacterium tuberculosis*. *N Engl J Med* 1993;**329**:2036.
- Richeldi L, Barnini S, Saltini C. Molecular diagnosis of tuberculosis. *Eur Respir J Suppl* 1995;**20**:689–700.
- Noordhoek GT, Mulder S, Wallace P, et al. Multicentre quality control study for detection of *Mycobacterium tuberculosis* in clinical samples by nucleic amplification methods. *Clin Microbiol Infect* 2004;**10**:295–301.
- Behr MA, Warren SA, Salomon H, et al. Transmission of *Mycobacterium tuberculosis* from patients smear-negative for acid-fast bacilli. *Lancet* 1999;**353**:444–9.
- Centers for Disease Control and Prevention. Nucleic acid amplification tests for tuberculosis (update). *JAMA* 2000;**284**:826.
- Sarmiento OL, Weigle KA, Alexander J, et al. Assessment by meta-analysis of PCR for diagnosis of smear-negative pulmonary tuberculosis. *J Clin Microbiol* 2003;**41**:3233–40.
- Flores LL, Pai M, Colford JM, et al. In-house nucleic acid amplification tests for the detection of *Mycobacterium tuberculosis* in sputum specimens: meta-analysis and meta-regression. *BMC Microbiology* 2005;**5**:55.
- Bossuyt P, Reitsma JB, Bruns DE, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. *Clin Chem* 2003;**49**:7–18.
- Irwig L, Macaskill P, Glasziou P, et al. Meta-analytic methods for diagnostic test accuracy. *J Clin Epidemiol* 1995;**48**:119–30.
- Deeks JJ. Systematic reviews of evaluations of diagnostic and screening tests. *BMJ* 2001;**323**:157–62.
- Buck A, Gart J. Comparison of a screening test and a reference test in epidemiologic studies. *Am J Epidemiol* 1966;**83**:586–92.
- Boyko EJ. Meta-analysis of Pap test accuracy. *Am J Epidemiol* 1995;**141**:680–9.
- Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and interpreted? *Stat Med* 2002;**21**:1559–73.
- Alcala L, Ruiz-Serrano MJ, Hernangomez S, et al. Evaluation of the upgraded amplified *Mycobacterium tuberculosis* direct test (Gen-Probe) for direct detection of *Mycobacterium tuberculosis* in respiratory and non-respiratory specimens. *Diagn Microbiol Infect Dis* 2001;**41**:51–6.
- Ausina V, Gamboa F, Gazapo E, et al. Evaluation of the semiautomated AbbotLX *Mycobacterium tuberculosis* assay for direct detection of *Mycobacterium tuberculosis* in respiratory specimens. *J Clin Microbiol* 1997;**35**:1996–2002.
- Barrett A, Magee JG, Freeman R. An evaluation of the BDProbeTec ET system for the direct detection of *Mycobacterium tuberculosis* in respiratory samples. *J Med Microbiol* 2002;**51**:895–8.
- Beavis KG, Licht MB, Jungking DL, et al. Evaluation of AMPLICOR PCR for direct detection of *Mycobacterium tuberculosis* from sputum specimens. *J Clin Microbiol* 1995;**33**:2582–6.
- Bennedsen J, Thomsen VO, Pfyffer GE, et al. Utility of PCR in diagnosing pulmonary tuberculosis. *J Clin Microbiol* 1996;**34**:1407–11.
- Bergmann JS, Keating WE, Woods GL. Clinical evaluation of the BDProbeTec ET system for rapid detection of *Mycobacterium tuberculosis*. *J Clin Microbiol* 2000;**38**:863–5.
- Bergmann JS, Woods GL. Clinical evaluation of the Roche AMPLICOR PCR *Mycobacterium tuberculosis* test for detection of *M tuberculosis* in respiratory specimens. *J Clin Microbiol* 1996;**34**:1083–5.
- Bergmann JS, Yuoh G, Fish G, et al. Clinical evaluation of the enhanced Gen-Probe amplified *Mycobacterium tuberculosis* direct test for rapid diagnosis of tuberculosis in prison inmates. *J Clin Microbiol* 1999;**37**:1419–25.
- Bodmer T, Mockl E, Muhlemann K, et al. Improved performance of Gen-Probe amplified *Mycobacterium tuberculosis* direct test when 500 instead of 50 microliters of decontaminated sediment is used. *J Clin Microbiol* 1996;**34**:222–3.
- Bogard M, Vincelette J, Antinazzi R, et al. Multicenter study of a commercial, automated polymerase chain reaction system for the rapid detection of *Mycobacterium tuberculosis* in respiratory specimens in routine clinical practice. *Eur J Clin Microbiol Infect Dis* 2001;**20**:724–31.
- Cartuyvels R, De Ridder C, Jonckheere S, et al. Prospective clinical evaluation of AmpliCor *Mycobacterium tuberculosis* PCR test as a screening method in a low-prevalence population. *J Clin Microbiol* 1996;**34**:2001–3.
- Chedore P, Jamieson FB. Routine use of the Gen-Probe MTD2 amplification test for detection of *Mycobacterium tuberculosis* in clinical specimens in a large public health mycobacteriology laboratory. *Diagn Microbiol Infect Dis* 1999;**35**:185–91.
- Cleary TJ, Roudel G, Casillas O, et al. Rapid and specific detection of *Mycobacterium tuberculosis* by using the Smart Cycler instrument and a specific fluorogenic probe. *J Clin Microbiol* 2003;**41**:4783–6.
- Coll P, Garrigo M, Moreno C, et al. Routine use of Gen-Probe amplified *Mycobacterium tuberculosis* direct (MTD) test for detection of *Mycobacterium tuberculosis* with smear-positive and smear-negative specimens. *Int J Tuberc Lung Dis* 2003;**7**:886–91.
- Dalovisio JR, Montenegro-James S, Kemmerly SA, et al. Comparison of the amplified *M tuberculosis* (MTB) direct test, AmpliCor MTB PCR and IS6110-PCR for detection of MTB in respiratory specimens. *Clin Infect Dis* 1996;**23**:1099–106.
- D'Amato RF, Wallman AA, Hochstein LH, et al. Rapid diagnosis of pulmonary tuberculosis by using Roche AMPLICOR *Mycobacterium tuberculosis* PCR test. *J Clin Microbiol* 1995;**33**:1832–4.
- De La Calle LJ, De La Calle MAJ, Rodriguez-Iglesias M. Evaluation of the BDProbeTec ET system as screening tool in the direct detection of *Mycobacterium tuberculosis* complex in respiratory specimens. *Diagn Microbiol Infect Dis* 2003;**47**:573–8.
- Denis O, Devaster JM, Vandenberg O, et al. Evaluation of ligase chain reaction for direct detection of *Mycobacterium tuberculosis* in respiratory specimens. *Zentralbl Bakteriol* 1998;**288**:59–65.
- Dilworth JP, Goyal M, Young DB, et al. Comparison of polymerase chain reaction for IS6110 and AmpliCor in the diagnosis of tuberculosis. *Thorax* 1996;**51**:320–2.
- Gallina M, Troupioti P, Rocco G, et al. Predicting culture results for *Mycobacterium tuberculosis* complex. Amplified *Mycobacterium tuberculosis* direct test and acid-fast bacilli microscopy. *Chest* 2000;**118**:28–32.
- Gamboa F, Fernandez G, Padilla E, et al. Comparative evaluation of initial and new versions of the Gen-Probe amplified *Mycobacterium tuberculosis* direct test for direct detection of *Mycobacterium tuberculosis* in respiratory and nonrespiratory specimens. *J Clin Microbiol* 1998;**36**:684–9.
- Gamboa F, Manterola JM, Lonca J, et al. Comparative evaluation of two commercial assays for direct detection of *Mycobacterium tuberculosis* in respiratory specimens. *Eur J Clin Microbiol Infect Dis* 1998;**17**:151–7.
- Gurkan O, Acican T, Gulbay B. Evaluation of an amplified *Mycobacterium tuberculosis* direct test in clinical specimens. *Int J Tuberc Lung Dis* 2002;**6**:538–41.
- Ichihama S, Iinuma Y, Tawada Y, et al. Evaluation of Gen-Probe amplified *Mycobacterium tuberculosis* direct test and Roche PCR-microwell plate hybridization method (AmpliCor *Mycobacterium*) for direct detection of mycobacteria. *J Clin Microbiol* 1996;**34**:130–3.
- Iinuma Y, Senda K, Fujihara N, et al. Comparison of the BDProbeTec ET system with the Cobas AmpliCor PCR for direct detection of *Mycobacterium tuberculosis* in respiratory samples. *Eur J Clin Microbiol Infect Dis* 2003;**22**:368–71.
- Iwamoto T, Sonobe T, Hayashi K. Loop-mediated isothermal amplification for direct detection of *Mycobacterium tuberculosis* complex, *M avium*, and *M intracellulare* in sputum samples. *J Clin Microbiol* 2003;**41**:2616–22.
- Jan IS, Hsueh PR, Teng LJ, et al. Evaluation of an automatic polymerase chain reaction assay for identification of *Mycobacterium tuberculosis* in respiratory specimens. *J Formos Med Assoc* 1998;**97**:204–9.
- Johansen IS, Thomsen VO, Johansen A, et al. Evaluation of a new commercial assay for diagnosis of pulmonary and nonpulmonary tuberculosis. *Eur J Clin Microbiol Infect Dis* 2002;**21**:455–60.



- 42 Jonsson B, Ridell M. The Cobas Amplicor MTB test for detection of Mycobacterium tuberculosis complex from respiratory and non-respiratory clinical specimens. *Scand J Infect Dis* 2003;**35**:372-7.
- 43 Kearns AM, Freeman R, Steward M, et al. A rapid polymerase chain reaction technique for detecting M tuberculosis in a variety of clinical specimens. *J Clin Pathol* 1998;**51**:922-4.
- 44 Kim SY, Park YJ, Kang SJ, et al. Comparison of the BDProbeTec ET system with the Roche COBAS AMPLICOR system for detection of Mycobacterium tuberculosis complex in the respiratory and pleural fluid specimens. *Diagn Microbiol Infect Dis* 2004;**49**:13-8.
- 45 Lebrun L, Mathieu D, Saulnier C, et al. Limits of commercial molecular tests for diagnosis of pulmonary tuberculosis. *Eur Respir J* 1997;**10**:1874-6.
- 46 Lemaitre N, Armand S, Vachee A, et al. Comparison of real-time PCR method and the Gen-Probe amplified Mycobacterium tuberculosis direct test for detection of Mycobacterium tuberculosis in pulmonary and nonpulmonary specimens. *J Clin Microbiol* 2004;**42**:4307-9.
- 47 Levadiotou S, Vriani G, Galanakis E, et al. Four-year experience of use of the Cobas Amplicor system for rapid detection of Mycobacterium tuberculosis complex in respiratory and nonrespiratory specimens in Greece. *Eur J Clin Microbiol Infect Dis* 2003;**22**:349-56.
- 48 Liu D, Jones SL, Baird R, et al. Use of Roche Amplicor and multiplex PCR for diagnosis of human mycobacterial infections. *Opportunistic Pathogens* 1997;**9**:51-5.
- 49 Lumb R, Davies K, Dawson D, et al. Multicenter evaluation of the Abbott LCx Mycobacterium tuberculosis ligase chain reaction assay. *J Clin Microbiol* 1999;**37**:3102-7.
- 50 Maugein J, Fourche J, Vacher S, et al. Evaluation of the BDProbeTec ET DTB assay(1) for direct detection of Mycobacterium tuberculosis complex from clinical samples. *Diagn Microbiol Infect Dis* 2002;**44**:151-5.
- 51 Mazzarelli G, Rindi L, Piccoli P, et al. Evaluation of the BDProbeTec ET system for direct detection of Mycobacterium tuberculosis in pulmonary and extrapulmonary samples: a multicenter study. *J Clin Microbiol* 2003;**41**:1779-82.
- 52 McHugh TD, Pope CF, Ling CL, et al. Prospective evaluation of BDProbeTec strand displacement amplification (SDA) system for diagnosis of tuberculosis in non-respiratory and respiratory samples. *J Med Microbiol* 2004;**53**:1215-9.
- 53 Miller N, Cleary T, Kraus G, et al. Rapid and specific detection of Mycobacterium tuberculosis from acid-fast bacillus smear-positive respiratory specimens and BacT/ALERT MP culture bottles by using fluorogenic probes and real-time PCR. *J Clin Microbiol* 2002;**40**:4143-7.
- 54 Moore DF, Curry JI. Detection and identification of Mycobacterium tuberculosis directly from sputum sediments by AMPLICOR PCR. *J Clin Microbiol* 1995;**33**:2686-91.
- 55 Moore G, Curry JI. Detection and identification of Mycobacterium tuberculosis directly from sputum sediments by ligase chain reaction. *J Clin Microbiol* 1998;**36**:1028-31.
- 56 O'Sullivan CE, Miller DR, Schneider PS, et al. Evaluation of Gen-Probe amplified Mycobacterium tuberculosis direct test by using respiratory and nonrespiratory specimens in a tertiary care center laboratory. *J Clin Microbiol* 2002;**40**:1723-7.
- 57 Piersimoni C, Callegaro A, Nista D, et al. Comparative evaluation of two commercial amplification assays for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. *J Clin Microbiol* 1997;**35**:193-6.
- 58 Piersimoni C, Callegaro A, Scarparo C, et al. Comparative evaluation of the new Gen-Probe Mycobacterium tuberculosis amplified direct test and the semiautomated Abbott LCx Mycobacterium tuberculosis assay for direct detection of Mycobacterium tuberculosis complex in respiratory and extrapulmonary specimens. *J Clin Microbiol* 1998;**36**:3601-4.
- 59 Piersimoni C, Scarparo C, Piccoli P, et al. Performance assessment of two commercial amplification assays for direct detection of Mycobacterium tuberculosis complex from respiratory and extrapulmonary specimens. *J Clin Microbiol* 2002;**40**:4138-42.
- 60 Reischl U, Lehn N, Wolf H, et al. Clinical evaluation of the automated COBAS AMPLICOR MTB assay for testing respiratory and nonrespiratory specimens. *J Clin Microbiol* 1998;**36**:2853-60.
- 61 Rohner P, Jahn EI, Ninet B, et al. Rapid diagnosis of pulmonary tuberculosis with the LCx Mycobacterium tuberculosis assay and comparison with conventional diagnostic techniques. *J Clin Microbiol* 1998;**36**:3046-7.
- 62 Rusch-Gerdes S, Richter E. Clinical evaluation of the semiautomated BDProbeTec ET system for the detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens. *Diagn Microbiol Infect Dis* 2004;**48**:265-70.
- 63 Scarparo C, Piccoli P, Rigon A, et al. Comparison of enhanced Mycobacterium tuberculosis amplified direct test with Cobas Amplicor Mycobacterium tuberculosis assay for direct detection of Mycobacterium tuberculosis complex in respiratory and extrapulmonary specimens. *J Clin Microbiol* 2000;**38**:1559-62.
- 64 Smith MB, Bergmann JS, Harris SL, et al. Evaluation of Roche Amplicor MTB assay for the detection of Mycobacterium tuberculosis in sputum specimens from prison inmates. *Diagn Microbiol Infect Dis* 1997;**27**:113-6.
- 65 Smith MB, Bergmann JS, Onorato M, et al. Evaluation of the enhanced amplified Mycobacterium tuberculosis direct test for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. *Arch Pathol Lab Med* 1999;**123**:1101-3.
- 66 Soini H, Agha SA, El-Fiky A, et al. Comparison of amplicor and 32-kilodalton PCR for detection of Mycobacterium tuberculosis from sputum specimens. *J Clin Microbiol* 1996;**34**:1829-30.
- 67 Tevere VJ, Hewitt PL, Dare A, et al. Detection of Mycobacterium tuberculosis by PCR amplification with pan-Mycobacterium primers and hybridization to an M tuberculosis-specific probe. *J Clin Microbiol* 1996;**34**:918-23.
- 68 Viinonen AH, Soini H, Marjamäki M, et al. Ligase chain reaction assay is clinically useful in the discrimination of smear-positive pulmonary tuberculosis from atypical mycobacterioses. *Ann Med* 2000;**32**:279-83.
- 69 Viveiros M, Pinheiro S, Moreira P, et al. Evaluation of a commercial ligase chain reaction assay for the diagnosis of pulmonary and extra-pulmonary tuberculosis. *Int J Tuberc Lung Dis* 1999;**3**:508-14.
- 70 Vuorinen P, Miettinen A, Vuento R, et al. Direct detection of Mycobacterium tuberculosis complex in respiratory specimens by Gen-Probe amplified Mycobacterium tuberculosis direct test and Roche Amplicor Mycobacterium tuberculosis test. *J Clin Microbiol* 1995;**33**:1856-9.
- 71 Wang JY, Lee LN, Chou CS, et al. Performance assessment of a nested-PCR assay (the rapid BAP-MTB) and the BDProbeTec ET system for detection of Mycobacterium tuberculosis in clinical specimens. *J Clin Microbiol* 2004;**43**:4599-603.
- 72 Wang SX, Tay L. Evaluation of three nucleic acid amplification methods for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. *J Clin Microbiol* 1999;**37**:1932-4.
- 73 Yam WC, Yuen KY, Seto WH. Direct detection of Mycobacterium tuberculosis in respiratory specimens using an automated DNA amplification assay and a single tube nested polymerase chain reaction (PCR). *Clin Chem Lab Med* 1998;**36**:597-9.
- 74 Yee YC, Gough A, Kumarasinghe G, et al. The pattern of utilisation and accuracy of a commercial nucleic acid amplification test for the rapid diagnosis of Mycobacterium tuberculosis in routine clinical practice. *Singapore Med J* 2002;**43**:415-20.
- 75 Yuen KY, Yam WC, Wong LP, et al. Comparison of two automated DNA amplification systems with a manual one-tube nested PCR assay for diagnosis of pulmonary tuberculosis. *J Clin Microbiol* 1997;**35**:1385-9.
- 76 Zolnir-Dovc M, Poljak M, Seme K, et al. Evaluation of two commercial amplification assays for detection of Mycobacterium tuberculosis complex in respiratory specimens. *Infection* 1995;**23**:216-21.
- 77 Centers for Disease Control, Prevention (CDC). *M tuberculosis nucleic acid amplification testing performance evaluation program*. Atlanta, CDC; 2004. <http://www.phppo.cdc.gov/mpep/pdf/mtb/0401naa.pdf> [accessed 10 September 2005].
- 78 Plyffer G, Welscher HM, Kissling P, et al. Comparison of the Mycobacteria Growth Indicator Tube (MGIT) with radiometric and solid culture for recovery of acid-fast bacilli. *J Clin Microbiol* 1997;**35**:364-8.
- 79 Kennedy DJ, Lewis WP, Barnes PF. Yield of bronchoscopy for the diagnosis of tuberculosis in patients with human immunodeficiency virus infection. *Chest* 1992;**102**:1040-4.
- 80 Baughman RP, Dohn MN, Loudon RG, et al. Bronchoscopy with bronchoalveolar lavage in tuberculosis and fungal infections. *Chest* 1991;**99**:92-7.
- 81 US Food and Drug Administration, Center for Devices and Radiological Health. *Gen-Probe® Amplified™ Mycobacterium Tuberculosis Direct (MTD) Test - P940034/S008, Part 2, pages 15-25*. <http://www.fda.gov/cdrh/pdf/P940034S008b.pdf> [accessed 10 September 2005].
- 82 Hadgu A. Discrepant analysis: a biased and an unscientific method for estimating test sensitivity and specificity. *J Clin Epidemiol* 1999;**52**:1231-7.
- 83 Joint Tuberculosis Committee of the British Thoracic Society. Control and prevention of tuberculosis in the United Kingdom: code of practice 2000. *Thorax* 2000;**55**:887-901.
- 84 Jindani A, Aber VR, Edwards EA, et al. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. *Am Rev Respir Dis* 1980;**121**:939-49.
- 85 Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. *J Clin Epidemiol* 2005;**58**:882-93.
- 86 Begg CB. Systematic reviews of diagnostic studies require study by study examination: first for heterogeneity and then for sources of heterogeneity. *J Clin Epidemiol* 2005;**58**:865-6.
- 87 Jouvessomme S, Cambau E, Trystam D, et al. Clinical utility of an amplification test based on ligase chain reaction in pulmonary tuberculosis. *Am J Respir Crit Care Med* 1998;**158**:1096-101.
- 88 Lim TK, Mukhopadhyay A, Gough A, et al. Role of clinical judgment in the application of a nucleic acid amplification test for the rapid diagnosis of pulmonary tuberculosis. *Chest* 2003;**124**:902-8.
- 89 Al Zaharani K, Al Jahdali H, Poirier L, et al. Yield of smear, culture and amplification tests from repeated sputum induction for the diagnosis of pulmonary tuberculosis. *Int J Tuberc Lung Dis* 2001;**5**:855-60.
- 90 Kwiatkowska S, Marczak J, Zieba M, et al. Clinical utility of a commercial ligase chain reaction kit for the diagnosis of smear-negative pulmonary tuberculosis. *Int J Tuberc Lung Dis* 1999;**3**:421-5.
- 91 Lim TK, Gough A, Chin NK, et al. Relationship between estimated pretest probability and accuracy of automated Mycobacterium tuberculosis assay in smear-negative pulmonary tuberculosis. *Chest* 2000;**118**:641-7.
- 92 Lim TK, Zhu D, Gough A, et al. What is the optimal approach for using a direct amplification test in the routine diagnosis of pulmonary tuberculosis? A preliminary assessment. *Respirology* 2002;**7**:351-7.



**THE CURRENT EVIDENCE ON DIAGNOSTIC ACCURACY OF COMMERCIAL BASED NUCLEIC ACID  
AMPLIFICATION TESTS FOR THE DIAGNOSIS OF PULMONARY TUBERCULOSIS.  
A META-REGRESSION ANALYSIS**

**APPENDIX – DETAILED STUDY SELECTION METHODOLOGY**

Stefania Greco, Enrico Girardi, Assunta Navarra, Cesare Saltini

## LITERATURE SEARCH

We used systematic methods to identify studies analysing diagnostic accuracy of commercial nucleic acid amplification tests (NAATs) for the diagnosis of pulmonary tuberculosis (TB).

An investigator (S.G.) developed a computerized search strategy to identify relevant studies published until 1 March 2005 in the Medline and Embase electronic databases.

This strategy employed key words (both controlled vocabulary and free text terms) and was divided into three parts,. each connected by the [AND] bullion. The first part mapped the search for tuberculosis, the second, more complexpart, mapped the search for nucleic acid amplification tests, while the final part limited the search to English-language studies. A detailed description of our search strategy is shown in fig S1. We first searched for articles in the Medline database. All duplicate articles found in the Embase database were excluded.

We updated the literature search in Medline through 1 July 2005 by employing the same search strategy. Subsequently, the references listed in articles previously retrieved were scrutinized.

### FIGURE S1

MEDLINE search strategy for studies on diagnostic capability of commercial NAAT for pulmonary tuberculosis

```
mycobacterium tuberculosis[MeSH Terms] OR (mycobacterium[Text Word] AND tuberculosis[Text Word])  
OR tuberculosis[MeSH Terms] OR tuberculosis[Text Word]  
AND  
((((molecular[Text Word] AND (("diagnostic techniques and procedures"[MeSH Terms]) OR  
(diagnostic[Text Word] AND (techniques[Text Word] OR tests[Text Word] OR methods[Text Word]))) OR  
direct[Text Word] AND (detection[Text Word] OR amplification[Text Word] OR identification[Text Word])  
AND (test[Text Word] OR assay[Text Word] OR system[Text Word] OR method[Text Word] OR  
technique[Text Word]) OR nucleic acid amplification techniques[MeSH Terms] OR ((nucleic[Text Word]  
AND acid[Text Word] AND amplification[Text Word]) OR (molecular[Text Word]) AND (test[Text Word] OR  
assay[Text Word] OR system[Text Word] OR method[Text Word] OR technique[Text Word]) OR  
amplification[Text Word] AND (gene[Text Word] OR genes[Text Word] OR genetic[Text Word] OR  
DNA[Text Word] OR deoxyribonucleic[Text Word] OR RNA[Text Word] OR ribonucleic[Text Word]) OR  
PCR[Text Word] OR polymerase chain reaction[MeSH Terms] OR (polymerase[Text Word] AND  
chain[Text Word] AND reaction[Text Word]) OR LCX[Text Word] OR LCR[Text Word] OR (ligase[Text  
Word] AND chain[Text Word] AND reaction[Text Word]) OR SDA[Text Word] OR (strand[Text Word] AND  
displacement[Text Word] AND amplification[Text Word] OR BDProbeTec[Text Word] OR MTD[Text Word]  
OR (mycobacterium [Text Word] AND direct[Text Word] AND test[Text Word]) OR (Amplicor[Text Word])  
OR (Cobas[Text Word] AND Amplicor[Text Word])))))))  
AND English[Lang]
```

## STUDY SELECTION PROCESS

To be included, a study had to 1) examine commercial NAAT diagnostic performance on respiratory samples (a percentage of <5% of non respiratory samples was tolerated); 2) apply *Mycobacterium tuberculosis* (MTB) culture performed on the same sample as reference standard for pulmonary TB diagnosis; 3) provide sufficient original data to permit calculation of sensitivity and/or specificity; and 4) be written in English. We excluded studies 1) reporting sensitivity and specificity “revised” by means of discrepant analysis; 2) analysing sample population used in different studies published by the same research group (only the article reporting on the largest number of samples was considered) and 3) including a percentage of gastric aspirates of >5%.

The selection of the studies to be included in the meta-analysis was based upon the above mentioned criteria. As assessing study relevance and extracting data require the use of judgement, two independent investigators reviewed the articles and disagreements were settled by consensus. The initial search strategy (fig S1) yielded a total of 3,302 citations and a further 41 were identified by checking the references of retrieved articles. A careful review of titles and abstracts eliminated 2,864 citations, that were clearly outside the scope of the meta-analysis. The relevance of the remaining 479 was judged by applying inclusion and exclusion criteria. After eliminating 73 reviews (or comments)<sup>1-73</sup> and 66 articles exploring technical issues related to the use of NAAT both for direct application on clinical specimens and for identification of *Mycobacterium tuberculosis* in culture<sup>74-139</sup>, we evaluated 340 studies reporting primary data on clinical utility of NAAT for TB.

Of the articles which did not analyse commercial NAAT, 171 used different types of home-grown PCR<sup>140-310</sup> and 25 evaluated two commercial NAAT which were withdrawn from the market more than seven years ago, i.e. the old version of Gen Probe MTD and the Q-beta replicase<sup>311-335</sup>. Although the Abbott Ligase Chain Reaction (LCx) test has been withdrawn from the market in 2002, we elected to include articles on LCx performance as this test is still used in many hospital laboratories.

The inclusion of a percentage above 5% of non respiratory samples lead to the exclusion of further 15 articles<sup>336-350</sup>. Although gastric aspirate examination is used for pulmonary TB diagnosis, the lower yield of both culture and NAAT on this type of sample could markedly and variably alter accuracy estimates<sup>343</sup>. Thus, we excluded 7 articles that evaluated a percentage of gastric aspirates higher than 5%<sup>351-357</sup>.

With the exception of 3 articles on commercial NAAT utility for pulmonary TB follow-up<sup>358-360</sup> and 8 articles not fulfilling inclusion criteria for different reasons<sup>361-368</sup>, the remaining 114 articles estimated sensitivity and specificity of commercial NAAT for pulmonary TB diagnosis. Among them, 39 did not provide data sufficient for computation of accuracy for AFB+ and/or




AFB- samples<sup>369-407</sup>, 3 were from authors publishing several reports on the same samples<sup>408-410</sup> and in 6 articles accuracy was analysed on a “per patient” basis, without taking into consideration the different number of specimens collected for each patient (from 2 to 6)<sup>411-416</sup>. The remaining 63 articles were finally included in the meta-analysis<sup>417-479</sup>. The reasons for exclusion are also outlined in Fig. S2.

Since 8 out of the 63 included articles analyzed 2 different commercial NAATs, 71 studies on the whole were available (56 on AFB+ and 60 on AFB- samples). The commercial NAATs evaluated were: Roche Amplicor MTB (25 studies), its entirely automated version, Cobas Amplicor MTB (10), E-MTD (14), BDProbeTecET (12), LCx (10). Overall, the 63 articles examined 51,160 samples: 5,729 MTB culture positive and 45,431 MTB culture negative. The median number of samples per study was 410 (IQR 247 to 662), with a median pulmonary TB prevalence of 0,14 (IQR 0,07-0,3).

A summary of the 63 included articles reporting the 2x2 table of true positives and negatives and false positives and negatives and the related diagnostic odds ratios is shown in Table S1.

**FIGURE S2**  
Study selection process



Legend.  
cNAAT, commercial nucleic acid amplification tests; AFB, acid fast bacilli

**Table S1.** Results of the 63 included studies

study	NAAT	AFB+ samples							AFB- samples					
		a/c	b/d	TPR	TNR	DOR	prevalence		a/c	b/d	TPR	TNR	DOR	prevalence
Beavis 1995 [420]	Amplicor	80/1	10/8	0,99	0,44	64	0,82		3/3	7/420	0,50	0,98	60	0,01
D'Amato 1995 [432]	Amplicor	13/1	5/17	0,93	0,74	44	0,39		21/20	9/899	0,51	0,99	105	0,04
Moore 1995 [457]	Amplicor	82/1	6/2	0,99	0,25	27	0,91		52/27	8/798	0,66	0,97	75	0,09
Vuorinen 1995 [473]	Amplicor	20/0	0/3	1	1	240	0,87		2/4	2/218	0,33	0,99	55	0,03
Zolnir-Dove 1995 [479]	Amplicor	40/0	3/0	1	0,14	13	0,93		8/2	9/219	0,80	0,99	97	0,04
Bennedsen 1996 [421]	Amplicor	413/39	0/36	0,91	1	762	0,93		123/79	254/6250	0,61	0,96	38	0,03
Bergmann 1996 [423]	Amplicor	40/1	1/10	0,98	0,91	400	0,79		8/12	5/879	0,40	0,99	117	0,02
Cartuyvels 1996 [427]	Amplicor	11/1	1/0	0,92	0,50	6	0,92		6/7	16/614	0,46	0,98	33	0,02
Dalovisio 1996 [431]	Amplicor	25/3	3/34	0,89	0,92	94	0,43		16/12	12/283	0,57	0,96	31	0,09
Dilworth 1996 [435]	Amplicor	11/1	0/1	0,92	1	22	0,92		-	-	-	-	-	-
Ichiyama 1996 [440]	Amplicor	74/0	5/10	1	0,67	296	0,83		45/2	26/257	0,94	0,87	222	0,14
Soini 1996 [469]	Amplicor	12/1	8/4	0,92	0,33	6	0,52		1/1	4/45	0,50	0,92	11	0,04
Tevere 1996 [470]	Amplicor	59/0	1/17	1	0,94	2006	0,77		16/7	4/558	0,70	0,99	319	0,04
Lebrun 1997 [448]	Amplicor	42/1	0/12	0,98	1	1008	0,78		9/17	0/14	0,34	1	14,82	0,64
Liu 1997 [451]	Amplicor	41/0	0/42	1	1	6888	0,49		2/0	0/1	1	1	8	0,57
Piersimoni 1997 [460]	Amplicor	-	-	-	-	-	-		6/1	2/272	0,86	0,99	816	0,02
Smith MB 1997 [467]	Amplicor	23/1	8/14	0,96	0,64	40	0,52		8/4	3/498	0,67	0,97	810	0,02
Yuen 1997 [478]*	Amplicor	48/3	2/3	0,94	0,60	24	0,91		11/8	4/130	0,58	0,97	45	0,12
Kearns 1998 [446]	Amplicor	37/1	2/7	0,97	0,78	130	0,81		8/13	0/24	0,44	1	30	0,46
Gamboa 1998 [438]*	Amplicor	176/0	28/27	1	0,49	339	0,76		24/23	0/477	0,51	1	995	0,09
Miller 2002 [456]	Amplicor	103/2	0/30	0,98	1	3090	0,78		-	-	-	-	-	-
Yee 2002 [477]	Amplicor	-	-	-	-	-	-		3/2	1/66	0,60	0,99	99	0,07
Cleary 2003 [429]	Amplicor	190/8	0/168	0,96	1	7980	0,54		-	-	-	-	-	-
Iinuma 2003 [441]*	Amplicor	-	-	-	-	-	-		6/4	0/304	0,60	1	912	0,03
Iwamoto 2003 [442]	Amplicor	12/0	2/13	1	0,87	156	0,44		8/0	1/30	1	0,97	480	0,21
Gamboa 1998 [438]*	Cobas Amplicor	176/0	28/27	1	0,49	339	0,76		28/19	0/477	0,60	1	1406	0,09
Jan 1998 [443]	Cobas Amplicor	19/2	0/7	0,91	1	133	0,75		15/4	4/537	0,79	0,99	503	0,03
Reischl 1998 [463]	Cobas Amplicor	42/2	1/10	0,95	0,91	210	0,80		6/7	4/571	0,46	0,99	122	0,02
Yam 1998 [476]	Cobas Amplicor	18/1	0/7	0,95	1	252	0,73		20/5	0/334	0,80	1	2672	0,07
Wang 1999 [475]*	Cobas Amplicor	-	-	-	-	-	-		5/1	6/152	0,83	0,96	127	0,04
Scarpato 2000 [466]*	Cobas Amplicor	95/2	0/11	0,98	1	1045	0,90		13/4	5/166	0,76	0,96	108	0,09
Bogard 2001 [426]	Cobas Amplicor	183/16	8/42	0,92	0,84	60	0,80		95/36	47/4650	0,73	0,99	261	0,03
Jonsson 2003 [445]	Cobas Amplicor	46/1	0/17	0,98	1	1564	0,73		42/19	6/746	0,69	0,99	275	0,08
Levidiotou 2003 [450]	Cobas Amplicor	189/6	15/40	0,97	0,73	84	0,78		21/38	30/7215	0,36	1	133	0,01
Kim 2004 [447]*	Cobas Amplicor	-	-	-	-	-	-		6/7	0/126	0,46	1	216	0,09
Bergmann 2000 [422]	BDProbeTecET	12/0	0/11	1	1	91	0,52		2/2	6/567	0,50	0,99	95	0,01
Barrett 2002 [419]	BDProbeTecET	99/2	2/64	0,98	0,97	1584	0,60		1/7	1/29	0,13	0,97	4	0,21
Johansen 2002 [444]	BDProbeTecET	85/0	0/11	1	1	3740	0,89		39/26	3/186	0,60	0,98	93	0,26
Maugein 2002 [453]	BDProbeTecET	43/0	0/6	1	1	1032	0,88		18/8	8/464	0,69	0,98	131	0,05
Piersimoni 2002 [462]*	BDProbeTecET	75/1	0/31	0,99	1	4650	0,71		11/4	2/207	0,73	1	285	0,07
De la Calle 2003 [433]	BDProbeTecET	21/0	0/1	1	1	84	0,95		9/2	2/442	0,82	0,99	995	0,02
Iinuma 2003 [441]*	BDProbeTecET	-	-	-	-	-	-		5/5	1/303	0,50	1	303	0,03
Mazzarelli 2003 [454]	BDProbeTecET	133/2	1/27	0,99	0,96	1796	0,83		35/14	6/343	0,71	0,98	143	0,12
McHugh 2004 [455]	BDProbeTecET	48/0	2/0	1	0,20	24	0,96		33/2	28/245	0,94	0,90	149	0,11
Kim 2004 [447]*	BDProbeTecET	-	-	-	-	-	-		7/6	7/119	0,54	0,94	18	0,10
Rusch-Gerd. 2004 [465]	BDProbeTecET	36/0	0/2	1	1	288	0,95		54/8	36/612	0,87	0,94	106	0,09
Wang 2004 [474]	BDProbeTecET	11/1	8/1	0,92	0,11	1,4	0,57		11/7	27/486	0,61	0,95	29	0,04
Bodmer 1996 [425]	E-MTD	14/0	0/19	1	1	1064	0,42		6/4	5/669	0,60	0,99	201	0,01
Gamboa 1998 [437]	E-MTD	48/0	0/19	1	1	3648	0,72		42/5	0/296	0,89	1	4973	0,14
Piersimoni 1998 [461]*	E-MTD	36/0	0/6	1	1	864	0,86		24/1	6/175	0,96	0,97	700	0,12
Bergmann 1999 [424]	E-MTD	13/0	2/7	1	0,78	528	0,59		15/8	10/949	0,65	0,99	178	0,02
Chedore 1999 [428]	E-MTD	189/0	7/286	1	0,98	15444	0,39		5/0	2/127	1	0,98	635	0,04
Smith MB 1999 [468]	E-MTD	14/1	0/7	0,93	1	196	0,68		5/0	13/243	1	0,99	77	0,02
Gallina 2000 [436]	E-MTD	75/6	5/15	0,93	0,75	37	0,80		27/9	68/155	0,75	0,70	7	0,14
Scarpato 2000 [466]*	E-MTD	89/8	0/11	0,92	1	245	0,90		13/4	6/165	0,76	0,96	89	0,09
Alcala 2001 [417]	E-MTD	77/2	1/2	0,98	0,67	77	0,96		28/8	39/506	0,78	0,93	45	0,06
Gurkan 2002 [439]	E-MTD	-	-	-	-	-	-		10/6	72/297	0,63	0,80	7	0,04
O'Sullivan 2002 [459]	E-MTD	30/0	1/61	1	0,98	3660	0,33		3/1	2/238	0,75	0,99	357	0,02
Piersimoni 2002 [462]*	E-MTD	71/5	2/29	0,93	0,94	206	0,71		10/5	0/209	0,67	1	836	0,07
Coll 2003 [430]	E-MTD	184/1	1/47	1	0,98	8648	0,79		52/23	3/2993	0,69	1	2256	0,02
Lemaitre 2004 [449]	E-MTD	-	-	-	-	-	-		3/5	1/20	0,38	0,95	12	0,28
Ausina 1997 [418]	LCx	139/2	20/26	0,99	0,57	90	0,75		15/16	3/299	0,48	0,99	93	0,09
Yuen 1997 [478]*	LCx	47/4	4/1	0,92	0,20	3	0,91		7/12	7/127	0,37	0,95	11	0,12
Denis 1998 [434]	LCx	7/0	0/1	1	1	28	0,88		2/0	4/196	1	0,98	196	0,01
Moore 1998 [458]	LCx	13/0	8/0	1	0,06	2	0,62		12/9	21/451	0,57	0,98	73	0,04
Piersimoni 1998 [461]*	LCx	33/3	0/6	0,92	1	132	0,86		16/9	6/175	0,64	0,97	56	0,12
Lumb 1999 [452]	LCx	65/1	10/63	0,99	0,86	410	0,47		27/26	12/1879	0,51	0,99	163	0,03
Rohner 1999 [464]	LCx	55/3	1/9	0,95	0,90	165	0,85		14/6	44/1869	0,70	0,98	99	0,01
Viveiros 1999 [472]	LCx	20/0	3/5	1	0,63	67	0,71		8/1	3/53	0,89	0,95	141	0,14
Wang 1999 [475]*	LCx	-	-	-	-	-	-		6/0	7/151	1	0,96	258	0,03
Viinanan 2000 [471]	LCx	23/1	0/9	0,96	1	414	0,73		3/4	5/202	0,43	0,98	30	0,03

**Legend to Table 1S**

\*, articles analysing two different commercial NAATs; a, true positives; c, false negatives; b, false positives; d, true negatives; TPR, true positive rate (sensitivity); TNR, true negative rate (specificity); DOR, diagnostic odds ratio. Prevalence was calculated as the proportion of *Mycobacterium tuberculosis* culture positive samples among AFB+ or AFB- sample population. In parentheses, reference number.



## EVALUATION OF THE PUBLICATION BIAS


Publication bias is the tendency on the part of investigators to publish (and of reviewers to accept for publication) manuscripts with more optimistic results. As meta-analysis collects the body of published studies on a specified topic, it may reinforce the impact of the selection of positive papers and report inflated pooled estimates of diagnostic accuracy<sup>480</sup>.

We used a funnel plot to evaluate primary studies for publication bias. In a funnel plot the diagnostic odds ratio (DOR) is plotted against a measure of its precision, such as standard error (that is inversely proportional to sample size). As random variation of DOR estimates are expected to be smaller among larger studies, while results from small studies be widely scattered, meta-analysis data should be symmetrically distributed in a funnel shaped area. If publication bias is present, i.e., a tendency of small studies to report positive results (or, better, small studies with negative results are lacking) is present an asymmetrical funnel plot will be obtained. The Begg and Mazumdar adjusted rank correlation test (between DOR and its variances)<sup>481</sup> and the Egger regression asymmetry test<sup>482</sup>, are used for the statistical analysis of the visual funnel graph.

In our case, although the Begg's test was not significant (AFB+ samples,  $p=0,202$ ; AFB- samples,  $p=0,170$ ), the visual inspection of both funnel plots revealed the presence of some asymmetry (figure S3) and the Egger's test indicated a significant correlation between  $\ln\text{DOR}$  and its standard error both for studies on AFB+ samples (regression coefficient 1,14,  $p=0.011$ ) and for studies on AFB- samples (regression coefficient 0,97  $p=0.022$ ).

**FIGURE S3**

Funnel plot with pseudo 95% confidence limits.



## REFERENCES

1. [No authors listed]. Rapid diagnostic tests for tuberculosis: what is the appropriate use? American Thoracic Society Workshop. *Am J Respir Care Med* 1997; 155 : 1804-14
2. Afghani B, Stutman HR. Diagnosis of tuberculosis: can the polymerase chain reaction replace acid-fast bacilli smear and culture? *J Infect Dis* 1995; 172(3): 903-5
3. Anonymous. PCR and the mis-diagnosis of active tuberculosis. *New Engl J Med* 1995; 332(15): 1043
4. Arias-Bouda LP, Kolk AH. PCR-based assays for the diagnosis of tuberculosis. *Int J Tuberc Lung Dis* 2001; 5(12):1163-64
5. Barnes PF, Bloch AB, Davidson PT, Snider DE. Tuberculosis in patients with human immunodeficiency virus infection. *N Engl J Med* 1991; 324: 1644-1650
6. Barnes PF. Rapid diagnostic tests for tuberculosis: progress but no gold standard. *Am J Respir Crit Care Med* 1997;155(5):1497-8
7. Baxter R. Large-scale use of PCR for detection of *Mycobacterium tuberculosis* in a routine mycobacteriology laboratory. *J Clin Microbiol* 1994; 32(1): 273-74
8. Burkardt HJ. Standardization and quality control of PCR analyses. *Clin Chem Lab Med.* 2000;38(2):87-91
9. Butt T, Ahmad RN, Kazmi SY, Afzal RK, Mahmood A. An update on the diagnosis of tuberculosis. *J Coll Physicians Surg Pak* 2003; 13(12): 728-34
10. Catanzaro A. Assessing the indications for rapid diagnostic tests for tuberculosis. *J Respir Dis* 2001; 22(4): 202-205
11. Catanzaro A. Value of direct amplified test for diagnosis of tuberculosis. *Lancet* 1996; 347: 1500-1501
12. Clarridge III JE. Large-scale use of PCR for detection of mycobacterium tuberculosis in a routine mycobacteriology laboratory. *J Clin Microbiol* 1994; 32(3): 860
13. Collazos J. Molecular biology applied to tuberculosis: The third landmark. *Chest* 1996; 110(6): 1381-82
14. Daniel TM. The rapid diagnosis of tuberculosis: a selective review. *J Lab Clin Med* 1990; 116(3): 277-82
15. Dawson D. Comparison of nucleic acid amplification test for tuberculosis. *J Clin Microbiol* 1999; 37(4): 1226
16. Doern GV. Diagnostic mycobacteriology: where are we today? *J Clin Microbiol* 1996; 34(8): 1873-6
17. Drobniewski FA, Caws M, Gibson A, Young D. Modern laboratory diagnosis of tuberculosis. *Lancet Infect Dis* 2003; 3: 141-7
18. Forbes BA. Critical assessment of gene amplification approaches on the diagnosis of tuberculosis. *Immunol Invest* 1997; 26(1-2): 105-16
19. Forbes BA. Introducing a molecular test into the clinical microbiology laboratory. *Arch Pathol Lab Med* 2003; 127: 1106-11
20. Freeman R, Magee JG, Watt B, Rayner AB. Being positive about the smear. *Thorax* 2001; 56(5): 417
21. From the Centers for Disease Control and Prevention. Update: Nucleic acid amplification tests for tuberculosis. *JAMA* 2000; 16; 284(7): 826
22. Frothingham R. Applications of the polymerase chain reaction to infectious disease diagnosis. *Ann Saudi Med* 1996; 16(6): 657-665
23. Garcia JE, Losada JP, Gonzalez Villaron L. Reliability of the polymerase chain reaction in the diagnosis of mycobacterial infection. *Chest* 1996; 110(1): 300-1
24. Garg SK, Tiwari RP, Singh R, Malhotra D, Ramnani VK, Prasad GBKS, Chandra R, Fraziano M, Colizzi V, Bisen PS. Diagnosis of tuberculosis : available technologies, limitations and possibilities. *J Clin Lab Anal* 2003; 17: 155-63
25. Gillespie SH, McHugh TD. Monitoring the therapy of pulmonary tuberculosis by nested polymerase chain reaction. *J Infect* 1997; 35(3): 324-25
26. Godfrey-Fausset P. Molecular diagnosis tuberculosis: the need for new diagnostic tools. *Thorax* 1995; 50: 709-11
27. Grosser M, Dittert DD, Luther T. Molecular detection of *M. tuberculosis* DNA in tuberculosis and sarcoidosis. *Diagn Mol Pathol* 2001; 10(1): 66-68
28. Grosset J Mouton Y. Is PCR a useful tool for the diagnosis of tuberculosis in 1995? *Tuberc Lung Dis* 1995 76 183 184

29. Hawkey PM. The role of polymerase chain reaction in the diagnosis of mycobacterial infections. *Rev Med Microbiol* 1994; 5(1): 21-32
30. Heifets L. Dilemmas and realities of rapid diagnostic tests for tuberculosis. *Chest* 2000;118(1):4-5
31. Hill CS. Molecular diagnostics for infectious diseases. *Journal of Clinical Ligand Assay* 1996; 19(1): 43-52
32. Ho TB, Shaw RJ. Diagnosis and management of tuberculosis. *Monaldi Arch Chest Dis* 1998; 53(4): 424-28
33. Hoorfar J, Wolffs P, Radstrom P. Diagnostic PCR: validation and sample preparation are two sides of the same coin. *APMIS* 2004; 112: 808-14
34. Huggett JF, McHugh TD, Zumla A. Tuberculosis: amplification-based clinical diagnostic techniques. *Int J Biochem Cell Biol* 2003; 35: 1407-12
35. Ieven M, Goossens H. Relevance of nucleic acid amplification techniques for diagnosis of respiratory tract infections in the clinical laboratory. *Clin Microbiol Rev* 1997; 10(2): 242-56
36. Ieven, Goossens H. Relevance of nucleic acid amplification techniques for diagnosis of respiratory tract infections in the clinical laboratory. *Clin Microbiol Rev* 1997; 10 (2): 242-256
37. Jolobe OM. PCR to detect M tuberculosis. *J Clin Pathol* 1999; 52(5): 399
38. Jonas V, Longiaru M. Detection of M.tuberculosis by molecular methods. *Clin Lab Med* 1997; 17: 119-28
39. Katoh VM. Advances in molecular diagnosis of tuberculosis. *MJAFI* 2003; 59: 182-86
40. Klatser PR. Amplification reactions in mycobacteriology. *J Microbiol Methods* 1995; 23(1): 75-87
41. Kreck TC, Curtis JR. Rapid diagnosis of pleural tuberculosis by polymerase chain reaction. *Am J Respir Crit Care Med* 1996; 154(6 Pt 1): 1919
42. LoBue PA, Catanzaro A. TB or not TB? Rapid tests for pulmonary tuberculosis. *J Respir Dis* 1997; 18(3): 299-308
43. LoBue PA, Catanzaro A. The diagnosis of tuberculosis. *Dis Mon* 1997; 43(4): 185-246
44. Lodha R, Kabra SK. Newer diagnostic modalities for tuberculosis. *Indian J Pediatr* 2004; 71(3): 221-7
45. Lodha R, Kabra SK. Newer diagnostic modalities for tuberculosis. *Indian J Pediatr* 2004; 71(3): 221-7
46. Macher A, Goosby E, Beller M. PCR and the misdiagnosis of active tuberculosis. *N Engl J Med* 1995; 332(2): 128-29
47. Meador J, Moore D, Weismuller P. Use of nucleic acid amplification tests in the diagnosis and management of tuberculosis. *West J Med.* 1996; 165(3): 140-41
48. Minh VD, Hanh LQ, Vu M. Clinical use of nucleic-acid-amplification tests. *Chest.* 2000; 118(3): 574-75
49. Murdoch DR. Molecular genetic methods in the diagnosis of lower respiratory tract infections. *APMIS.* 2004; 112(11-12): 713-27
50. Pai M. The accuracy and reliability of nucleic acid amplification tests in the diagnosis of tuberculosis. *Natl Med J India* 2004; 17(5): 233-6
51. Piersimoni C, Scarparo C. Relevance of Commercial Amplification Methods for Direct Detection of Mycobacterium tuberculosis Complex in Clinical Samples. *J Clin Microbiol* 2003; 41(12): 5355-65
52. Raoult D. Predictive value of PCR applied to clinical samples for Mycobacterium tuberculosis detection. *J Clin Microbiol* 1994; 32(1): 273
53. Rattan A. PCR for the detection of Mycobacterium tuberculosis DNA. *Natl Med J India.* 1995; 8(4): 179-80
54. Richeldi L, Barnini S, Saltini C. Molecular diagnosis of tuberculosis. *Eur Respir J Suppl* 1995; 20: 689s-700s
55. Roth A, Schaberg T, Mauch H. Molecular diagnosis of tuberculosis: current clinical validity and future perspectives. *Eur Respir J* 1997; 10(8): 1877-91
56. Saltini C. Direct amplification of Mycobacterium tuberculosis deoxyribonucleic acid in paucibacillary tuberculosis. *Eur Respir J* 1998; 11(6): 1215-7
57. Schluger NW, Condos R, Levis S, Rom WN. PCR for the detection of Mycobacterium tuberculosis DNA. *Natl Med J India* 1995; 8: 179-80
58. Schluger NW, Rom WN. The polymerase chain reaction in the diagnosis and evaluation of pulmonary infections. *Am J Respir Crit Care Med* 1995; 152(1): 11-6



59. Schluger NW. Changing approaches in the diagnosis of tuberculosis. *Am J Respir Crit Care Med* 2001; 164: 2020-4
60. Schluger NW. The diagnosis of tuberculosis: what's old, what's new. *Semin Respir Infect* 2003; 18(4): 241-8
61. Shah A, Rauf Y. Newer methods for the laboratory diagnosis of tuberculosis. *Jk Practitioner* 2001; 8(4): 266-269
62. Soini H, Viljanen MK. Gene amplification in the diagnosis of mycobacterial infections. *APMIS*. 1997; 105(5): 345-53
63. Su WJ. Recent advances in the molecular diagnosis of tuberculosis. *J Microbiol Immunol Infect* 2002; 35(4): 209-14
64. Trinker M, Hoffer G, Sill H. False-positive diagnosis of tuberculosis with PCR. *Lancet* 1996; 348(9038): 1388
65. Tsilimigras CWA, Steyn LM. The rapid laboratory diagnosis of tuberculosis. *South Afr Med J* 1993; 83(9): 699
66. Van Helden PD, Hoal-Van Helden EG. Molecular answers to tuberculous questions. *Lancet* 2000; 356(9248): s61
67. Whelen AC, Persing DH. The role of nucleic acid amplification and detection in the clinical microbiology laboratory. *Annu Rev Microbiol* 1996; 50: 349-73
68. Wilson SM. Detection of *Mycobacterium tuberculosis* by a colorimetric polymerase chain reaction. *Methods Mol Biol* 1998; 101: 363-80
69. Wolska-Goszka L, Dubaniewicz A, Slominski JM. Utility of PCR in bacteriological diagnosis of tuberculosis. *Med Sci Monit* 1997; 3(5): 749-751
70. Woods GL. Molecular methods in the detection and identification of mycobacterial infections. *Arch Pathol Lab Med* 1999; 123(11): 1002-06
71. Woods GL. Molecular techniques in mycobacterial detection. *Arch Pathol Lab Med* 2001; 125(1): 122-26
72. Woods GL. The mycobacteriology laboratory and new diagnostic techniques. *Infect Dis Clin North Am* 2002; 16(1): 127-44
73. Yang S, Rothman RE. PCR-based diagnostics for infectious diseases: uses limitations and future applications in acute-care settings. *Lancet Infect Dis* 2004; 4: 337-348
74. Aldous WK, Pounder JI, Cloud JL, Woods GL. Comparison of six methods of extracting *Mycobacterium tuberculosis* DNA from processed sputum for testing by quantitative real-time PCR. *J Clin Microbiol* 2005; 43(5): 2471-3
75. Boddingtonhaus B, Rogall T, Flohr T, Blocker H, Bottger EC. Detection and identification of mycobacteria by amplification of rRNA. *J Clin Microbiol* 1990; 28: 1751-59
76. Bollela VR, Sato DN, Fonseca BA. McFarland nephelometer as a simple method to estimate the sensitivity of the polymerase chain reaction using *Mycobacterium tuberculosis* as a research tool. *Braz J Med Biol Res* 1999; 32(9): 1073-6
77. Cormican M, Glennon M, Riain UN, Flynn J. Multiplex PCR for identifying mycobacterial isolates. *J Clin Pathol* 1995; 48(3): 203-05
78. Das S, Paramasivan CN, Lowrie DB, Prabhakar R, Narayanan PR. IS6110 restriction fragment length polymorphism typing of clinical isolates of *Mycobacterium tuberculosis* from patients with pulmonary tuberculosis in Madras, South India. *Tuber Lung Dis* 1995; 76: 550-554
79. De Beenhouwer H, Liang Z, De Rijk P, Van Eekeren C, Portaels F. Detection and identification of mycobacteria by DNA amplification and oligonucleotide-specific capture plate hybridization. *J Clin Microbiol* 1995; 33(11): 2994-98
80. Desjardin LE, Perkins MD, Teixeira L, Cave MD et al. Alkaline decontamination of sputum adversely affects the stability of mycobacterial mRNA. *J Clin Microbiol* 1996; 34: 2435-39
81. de Wit D, Wootton M, Allan B, Steyn L. Simple method for production of internal control DNA for *Mycobacterium tuberculosis* polymerase chain reaction assays. *J Clin Microbiol* 1993; 31(8): 2204-7
82. Diaz R, Montoro E, Maestre JL, Echemendia M, Valdivia JA. Polymerase chain reaction for the detection of *Mycobacterium tuberculosis* complex. *Mem Inst Oswaldo Cruz* 1994; 89(2): 211-12
83. Doucet-Populaire F, Lalande V, Carpentier E, Bourgoin A, Dailloux M, Bollet C, Vachee A, Moinard D, Texier-Maugein J, Carbonnelle B, Grosset J. A blind study of the polymerase chain reaction for the detection of *Mycobacterium tuberculosis* DNA. *Azay Mycobacteria Study Group. Tuber Lung Dis* 1996; 77(4): 358-62

84. Dziadek J, Wolinska I, Sajduda A, Dela A, McFadden JJ. IS1607, a single-copy insertion sequence-related element of the *Mycobacterium tuberculosis* complex. *Int J Tuberc Lung Dis* 2000; 4(11): 1078-81
85. Eisenach KD, Cave D, Bates JH, Crawford JT. Polymerase chain reaction amplification of a repetitive DNA sequence specific for *Mycobacterium tuberculosis*. *J Infect Dis* 1990; 161: 977-81
86. Forbes B, Hicks K. Substances interfering with direct detection of *Mycobacterium tuberculosis* in clinical specimens by PCR: effects of bovine serum albumin. *J Clin Microbiol* 1996; 34(9): 2125-28
87. Fries JWU, Patel RJ, Piessens WF, Wirth DF. Detection of untreated mycobacteria by using polymerase chain reaction and specific DNA probes. *J Clin Microbiol* 1991; 29: 1744-47
88. Fries JWU, Patel RJ, Piessens WF, Wirth DF. Genus and species-specific DNA probes to identify *Mycobacteria* using the polymerase chain reaction. *Mol Cell Probes* 1990; 4: 87-105
89. Gillespie SH, McHugh TD, Newport LE. Specificity of IS6110-based amplification assays for *Mycobacterium tuberculosis* complex. *J Clin Microbiol* 1997; 35(3): 799-801
90. Githui WA, Wilson SM, Drobniewski FA. Specificity of IS6110-based DNA fingerprinting and diagnostic techniques for *Mycobacterium tuberculosis* complex. *J Clin Microbiol* 1999; 37(4): 1224-26
91. Glennon M, Smith T, Cormican M, Noone D, Barry T, Maher M, Dawson M, Gilmartin JJ, Gannon F. The ribosomal intergenic spacer region: a target for the PCR based diagnosis of tuberculosis. *Tuber Lung Dis* 1994; 75(5): 353-60
92. Haas WH, Ray Butler W, Woodley CL, Crawford JT. Mixed linker polymerase chain reaction: a new method for rapid fingerprinting of isolates of the *Mycobacterium Tuberculosis* complex. *J Clin Microbiol* 1993; 31: 1293-98
93. Hance AJ, Grandchamp B, Levy-Frebault V, Lecossier D, Rauzier J, Bocart D, Gicquel B. Detection and identification of mycobacteria by amplification of mycobacterial DNA. *Mol Microbiol* 1989; 3: 843-49
94. Heyderman RS, Goyal M, Roberts P, Ushewokunze S, Zizhou S, Marshall BG, Makombe R, Van Embden JD, Mason PR, Shaw RJ. Pulmonary tuberculosis in Harare, Zimbabwe: analysis by spoligotyping. *Thorax* 1998; 53(5): 346-50
95. Hellyer TJ, DesJardin LE, Assaf MK, Bates JH, Cave D, Eisenach KD. Specificity of IS6110-based amplification assay for *Mycobacterium tuberculosis* complex. *J Clin Microbiol* 1996; 34: 2843-46
96. Hermans PW, Schuitema AR, Van Soolingen D, Verstynen CPHJ, Bik EM, Thole JER, Kolk AHJ, Van Embden JDA. Specific detection of *Mycobacterium tuberculosis* complex strains by polymerase chain reaction. *J Clin Microbiol* 1990; 28: 1204-13
97. Hermans PW, van Soolingen D, Dale JW, Schuitema AR, McAdam RA, Catty D, van Embden JD. Insertion element IS986 from *Mycobacterium tuberculosis*: a useful tool for diagnosis and epidemiology of tuberculosis. *J Clin Microbiol* 1990; 28(9): 2051-8
98. Iovannisci DM, Winn-deen ES. Ligation amplification and fluorescence detection of *Mycobacterium tuberculosis* DNA. *Mol Cell Probes* 1993; 7: 35-43
99. Kamerbeek J, Schouls I, Kolk A, Van Agterveld M, Van Soolingen D, Kuijper S, Bunschoten A, Molhuizen H, Shaw R, Goyal M, Van Embden J. Simultaneous detection and strain differentiation of *Mycobacterium tuberculosis* for diagnosis and epidemiology *J Clin Microbiol* 1997; 35(4): 907-14
100. Kikuchi Y, Oka S, Kimura S, Mitamura K, Shimada K. Clinical application of the polymerase chain reaction for a rapid diagnosis of *Mycobacterium tuberculosis* infection. *Intern Med* 1992; 31(8): 1016-22
101. Kolk AH, Noordhoek GT, de Leeuw O, Kuijper S, van Embden JD. *Mycobacterium smegmatis* strain for detection of *Mycobacterium tuberculosis* by PCR used as internal control for inhibition of amplification and for quantification of bacteria. *J Clin Microbiol* 1994; 32(5): 1354-6
102. Kontos F, Petinaki E, Gitti Z, Costopoulos C, Anagnostou S, Tselentis I, Maniatis AN. Combined use of the fully automated Bactec MGIT 960 System and a PCR-restriction fragment length polymorphism analysis for routine detection and identification of mycobacteria from clinical samples. *J Microbiol Methods* 2003; 52(1): 137-40
103. Lin IJ, Che MJ, Yeh A, Hwang JJ, Wei CY, Tsao WL, Lee CP. Comparison of the sensitivity and specificity of an automatic ligase chain reaction assay system with a one-step polymerase

- chain reaction assay in the diagnosis of *Mycobacterium tuberculosis* complex. *Changgeng Yi Xue Za Zhi* 1999; 22(2): 204-11
104. Linton CJ, Jalal H, Leeming JP, Millar MR. Rapid discrimination of *Mycobacterium tuberculosis* strains by random amplified polymorphic DNA analysis. *J Clin Microbiol* 1994; 32: 2169-74
  105. Little MC, Andrews J, Moore R, Bustos S, Jones L, Embres C, Durmowicz G, Harris J, Berger D, Yanson K, Rostkowski C, Yursis D, Price J, Fort T, Walters A, Collis M, Llorin O, Wood J, Failing F, O'Keefe C, Scrivens B, Pope B, Hansen T, Marino K, Williams K, Boenisch N. Strand displacement amplification and homogeneous real-time detection incorporated in a second-generation DNA probe system, BDProbeTecET. *Clin Chem* 1999; 45(6): 777-84
  106. Little MC, Spears PA, Shank DD. Nucleotide sequence and strand displacement amplification of the 70K protein gene from mycobacteria. *Mol Cell Probes* 1994; 8(5): 375-84
  107. Mulcahy GM, Kaminski ZC, Albanese EA, Sood R, Pierce M. IS6110-based PCR methods for detection of *Mycobacterium tuberculosis*. *J Clin Microbiol* 1996; 34(5): 1348-9
  108. Niemann S, Harmsen D, Rusch-Gerdes S, Richter E. Differentiation of clinical *Mycobacterium tuberculosis* complex isolates by *gyrB* DNA sequence polymorphism analysis. *J Clin Microbiol* 2000; 38(9): 3231-34
  109. Noordhoek GT, Kolk AHJ, Bjune G, Catty D, Dale JW, Fine PEM, Godfrey-Fausset P, Cho S, Shinnick T, Svenson SB, Wilson S, Van Embden JDA. Sensitivity and specificity of PCR for detection of *Mycobacterium tuberculosis*: a blind comparison study among seven laboratories. *J Clin Microbiol* 1994; 32: 277-84
  110. Noordhoek GT, van Embden JD, Kolk AH. Reliability of nucleic acid amplification for detection of *Mycobacterium tuberculosis*: an international collaborative quality control study among 30 laboratories. *J Clin Microbiol* 1996; 34(10): 2522-5
  111. Noordhoek GT, Van Embden JDA, Kolk AHJ. Questionable reliability of the polymerase chain reaction in the detection of *Mycobacterium tuberculosis*. *N Eng J Med* 1993; 329: 2036
  112. Oggioni MR, Fattorini L, Li B, De Milito A, Zazzi M, Pozzi G, Orefici G, Valensin PE. Identification of *Mycobacterium tuberculosis* complex, *Mycobacterium avium* and *Mycobacterium intracellulare* by selective nested polymerase chain reaction. *Mol Cell Probes* 1995; 9(5): 321-26
  113. Patel RJ, Fries JWU, Piessens WF, Wirth DF. Sequence analysis and amplification by polymerase chain reaction of cloned DNA fragment for identification *Mycobacterium tuberculosis*. *J Clin Microbiol* 1990; 28: 513-18
  114. Patel S, Yates M, Sauders NA. PCR Enzyme Linked Immunosorbent Assay and partial rRNA gene sequencing: a rational approach to identifying mycobacteria. *J Clin Microbiol* 1997; 35: 2375-23
  115. Peneau A, Moinard D, Berard I, Pascal O, Moisan JP. Detection of mycobacteria using the polymerase chain reaction. *Eur J Clin Microbiol Infect Dis* 1992; 11(3): 270-71
  116. Plikaytis BB, Eisenach KD, Crawford JT, Shinnick TM. Differentiation of *Mycobacterium tuberculosis* and *Mycobacterium bovis* BCG by a polymerase chain reaction assay. *Mol Cell Probes* 1991; 5(3): 215-9
  117. Ridderhof JC, Williams LO, Legois S, Shult PA, Metchock B, Kubista LN, Handsfield JH, Fehd RJ, Robinson PH. Assessment of Laboratory Performance of Nucleic Acid Amplification Tests for Detection of *Mycobacterium tuberculosis*. *J Clin Microbiol* 2003; 41(11): 5258-61
  118. Rodrigo G, Kallenius G, Hoffmann E, Svenson SB. Diagnosis of mycobacterial infections by PCR and restriction enzyme digestion. *Lett Appl Microbiol* 1992; 15(2): 41-4
  119. Ross BC, Dwyer B. Rapid simple method for typing isolates of *Mycobacterium tuberculosis* by using the polymerase chain reaction. *J Clin Microbiol* 1993; 31: 329-34
  120. Shah JS, Liu J, Buxton D, Stone B, Nietupski R, Olive DM, King W, Klinger JD. Detection of *Mycobacterium tuberculosis* directly from spiked human sputum by Q-beta replicase-amplified assay. *J Clin Microbiol* 1995; 33(2): 322-328
  121. Soini H, Bottger EC, Viljanen MK. Identification of mycobacteria by PCR-based sequence determination of the 32-kilodalton protein gene. *J Clin Microbiol* 1994; 32(12): 2944-7
  122. Spargo CA, Fraiser MS, Van Cleve M, Wright DJ, Nycz CM, Spears PA, Walker GT. Detection of *M. tuberculosis* DNA using thermophilic strand displacement amplification. *Mol Cell Probes* 1996; 10(4): 247-56
  123. Spargo CA, Haaland PD, Jurgensen SR, Shank DD, Walker GT. Chemiluminescent detection of strand displacement amplified DNA from species comprising the *Mycobacterium tuberculosis* complex. *Mol Cell Probes* 1993; 7(5): 395-404

124. Suffys P, Palomino JC, Cardoso Leao S, Espitia C, Cataldi A, Alito A, Velasco M, Robledo J, Fernandez J, da Silva Rosa P, Romano MI. Evaluation of the polymerase chain reaction for the detection of *Mycobacterium tuberculosis*. *Int J Tuberc Lung Dis* 2000; 4(2): 179-83
125. Telenti A., Marchesi F, Balz M, Balli F, Bottger EC, Bodmer T. Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. *J Clin Microbiol* 1993; 31: 175-78
126. Tortoli E, Nanetti A, Piersimoni C, Cichero P, Farina C, Mucignat G, Scarparo C, Bartolini L, Valentini R, Nista D, Gesu G, Tosi CP, Crovatto M, Brusarosco G. Performance assessment of new multiplex probe assay for identification of mycobacteria. *J Clin Microbiol* 2001; 39(3): 1079-84
127. Van der Vliet GM, Schukkink RA, van Gemen B, Schepers P, Klatser PR. Nucleic acids sequence-based amplification (NASBA) for the identification of mycobacteria. *J Gen Microbiol* 1993; 139: 2423-29
128. Walker GT, Fraiser MS, Schram JL, Little MC, Nadeau JG, Malinowski DP. Strand displacement amplification –an isothermal, in vitro DNA amplification technique. *Nucleic Acids Res* 1992; 20: 1691-96
129. Walker GT, Linn CP, Nadeau JG. DNA detection by strand displacement amplification and fluorescence polarization with signal enhancement using a DNA binding protein. *Nucleic Acids Res* 1996; 24(2): 348-53
130. Walker GT, Linn CP. Detection of *Mycobacterium tuberculosis* DNA with thermophilic strand displacement amplification and fluorescence polarization. *Clin Chem* 1996; 42(10): 1604-8
131. Walker GT, Little MC, Nadeau JG, Shank DD. Isothermal in vitro amplification of DNA by a restriction enzyme/DNA polymerase system. *Proc Natl Acad Sci U S A* 1992; 89(1): 392-6
132. Walker GT, Nadeau JG, Linn CP, Devlin RF, Dandliker WB. Strand displacement amplification (SDA) and transient-state fluorescence polarization detection of *Mycobacterium tuberculosis* DNA. *Clin Chem* 1996; 42(1): 9-13
133. Walker GT, Nadeau JG, Linn CP. A DNA probe assay using strand displacement amplification (SDA) and filtration to separate reacted and unreacted detector probes. *Mol Cell Probes* 1995; 9(6): 399-403
134. Walker GT, Nadeau JG, Spears PA, Schram JL, Nycz CM, Shank DD. Multiplex strand displacement amplification (SDA) and detection of DNA sequences from *Mycobacterium tuberculosis* and other mycobacteria. *Nucleic Acids Res* 1994; 22: 2670-77
135. Wei CY, Lee CN, Chu CH, Hwang JJ, Lee CP. Determination of the sensitivity and specificity of PCR assays using different target DNAs for the detection of *Mycobacterium tuberculosis*. *Kaohsiung J Med Sci* 1999; 15(7): 396-405
136. Wilton S, Cousins D. Detection and identification of multiple mycobacterial pathogens by DNA amplification in a single tube. *PCR Methods Appl* 1992; 1(4): 269-73
137. Wong DA, Yip PC, Tse DL, Tung VW, Cheung DT, Kam KM. Routine use of a simple low-cost genotypic assay for the identification of mycobacteria in a high throughput laboratory. *Diagn Microbiol Infect Dis* 2003; 47(2): 421-6
138. Zolg JW, Philippi-Schulz S. The superoxide dismutase gene, a target for detection and identification of mycobacteria by PCR. *J Clin Microbiol* 1994; 32: 2801-12
139. Zwadyk P Jr, Down JA, Myers N, Dey MS. Rendering of mycobacteria safe for molecular diagnostic studies and development of a lysis method for strand displacement amplification and PCR. *J Clin Microbiol* 1994; 32(9): 2140-6
140. Abe C, Hirano K, Wada M, Kazumi Y, Takahashi M, Fukasawa Y, Yoshimura T, Miyagi C, Goto S. Detection of *Mycobacterium tuberculosis* in clinical specimens by polymerase chain reaction and Gen-Probe Amplified *Mycobacterium Tuberculosis* Direct Test. *J Clin Microbiol* 1993; 31(12): 3270-74
141. Afghani B, Lieberman JM, Duke MB, Stutman HR. Comparison of quantitative polymerase chain reaction, acid fast bacilli smear, and culture results in patients receiving therapy for pulmonary tuberculosis. *Diagn Microbiol Infect Dis* 1997; 29(2): 73-9
142. Afghani B, Stutman HR. Polymerase chain reaction for diagnosis of *M. tuberculosis*: comparison of simple boiling and a conventional method for DNA extraction. *Biochem Mol Med* 1996; 57(1): 14-8
143. Ahmed N, Mohanty AK, Mukhopadhyay U, Batish VK, Grover S. PCR-based rapid detection of *Mycobacterium tuberculosis* in blood from immunocompetent patients with pulmonary tuberculosis. *J Clin Microbiol* 1998; 36(10): 3094-95



144. Albay A, Kisa O, Baylan O, Doganci L. The evaluation of FASTPlaqueTB test for the rapid diagnosis of tuberculosis. *Diagn Microbiol Infect Dis* 2003; 46(3): 211-5 8
145. Almeda J, Garcia A, Gonzalez J, Quinto L, Ventura PJ, Vidal R, Rufi G, Martinez JA, Jimenez de Anta MT, Trilla A, Alonso PL. Clinical evaluation of an in-house IS6110 polymerase chain reaction for diagnosis of tuberculosis. *Eur J Clin Microbiol Infect Dis* 2000; 19(11): 859-67
146. Altamirano M, Kelly MT, Wong A, Bessuille ET, Black WA, Smith JA. Characterization of a DNA probe for detection of *Mycobacterium tuberculosis* complex in clinical samples by polymerase chain reaction. *J Clin Microbiol* 1992; 30(8): 2173-2176
147. Amicosante M, Richeldi L, Trenti G, Paone G, Campa M, Bisetti A, Saltini C. Inactivation of polymerase inhibitors for *Mycobacterium tuberculosis* DNA amplification in sputum using capture resin. *J Clin Microbiol* 1995; 33 (3): 629-630
148. Andersen AB, Thybo S, Godfrey-Faussett P, Stoker NG. Polymerase chain reaction for detection of *Mycobacterium tuberculosis* in sputum. *Eur J Clin Microbiol Infect Dis* 1993;12(12):922-27
149. Araj GF, Talhouk RS, Itani LY, Jaber W, Jamaledine GW. Comparative performance of PCR-based assay versus microscopy and culture for the direct detection of *Mycobacterium tuberculosis* in clinical respiratory specimens in Lebanon. *Int J Tuberc Lung Dis* 2000; 4(9): 877-81
150. Arimura M, Ohuchi T, Suzuki Y, Hishinuma A, Oikawa S, Sato J, Ieiri T. Clinical significance of direct detection of *Mycobacterium tuberculosis* in respiratory specimens by polymerase chain reaction. *Dokkyo J Med Sci* 1996; 23: 143-148
151. Aslanzadeh J, de la Viuda M, Fille M, Smith WB, Namdari H. Comparison of culture and acid-fast bacilli stain to PCR for detection of *Mycobacterium tuberculosis* in clinical samples. *Mol Cell Probes* 1998; 12(4): 207-11
152. Bahrmand AR, Bakayev VV, Babaei MH. - Use of polymerase chain reaction for primary diagnosis of pulmonary tuberculosis in the clinical laboratory. *Scand J Infect Dis* 1996; 28(5): 469-72
153. Beige J, Lokies J, Schaberg T, Finckh U, Fischer M, Mauch H, Lode H, Kohler B, Rolfs A. - Clinical evaluation of a *Mycobacterium tuberculosis* PCR assay. *J Clin Microbiol* 1995; 33(1): 90-5
154. Bhattacharya B. Karak K. Ghosal AG. Roy A. Das S. Dandapat P. Khetawat D. Mondal DK. Bhattacharya S. Chakrabarti S. Development of a new sensitive and efficient multiplex polymerase chain reaction (PCR) for identification and differentiation of different mycobacterial species. *Tropical Medicine & International Health* 2003; 8(2): 150-7
155. Bi HG, Saito A, Koide M, Ishimine T, Futenma M, Yamashiro Y, Kusano N, Kawakami K. Detection of *Mycobacterium tuberculosis* in clinical specimens by polymerase chain reaction method. *Kansenshogaku Zasshi* 1995; 69(3): 272-79
156. Bieger WP, Grabnitz F, Pardos D, Raith H, Feldmann K. Direct detection of *Mycobacterium tuberculosis* in clinical samples: PCR methods in comparison to conventional diagnostic and clinical measures. *Klinisches Labor* 1993; 39(9): 599-605
157. Bindayna KM, Thani A, Baig B, Botta GA. Rapid diagnosis of *Mycobacterium tuberculosis* by multiplex polymerase chain reaction from clinical specimens. *J Commun Dis* 2001; 33(4): 252-60
158. Borun M, Sajduda A, Pawlowska I, McFadden JJ, Dziadek J. Detection of *Mycobacterium tuberculosis* in clinical samples using insertion sequences IS6110 and IS990. *Tuberculosis (Edinb)* 2001;81(4):271-78
159. Brisson-Noel A, Gicquel B, Lecossier D, Levy-Frebault V, Nassif X, Hance AJ. Rapid diagnosis of tuberculosis by amplification of mycobacterial DNA in clinical samples. *Lancet* 1989; 2(8671): 1069-71
160. Brisson-Noel, A., C. Aznar, C. Chureau, S. Nguyen, C. Pierre, M. Bartoli, R. Bonete, G. Pialoux, B. Gicquel, Garrigue G. Diagnosis of tuberculosis by DNA amplification in clinical practice. *Lancet* 1991; 338: 364-66
161. Broccolo F, Scarpellini P, Locatelli G, Zingale A, Brambilla AM, Cichero P, Sechi LA, Lazzarin A, Lusso P, Malnati MS. Rapid diagnosis of mycobacterial infections and quantitation of *Mycobacterium tuberculosis* load by two real-time calibrated PCR assays. *J Clin Microbiol* 2003; 41(10): 4565-72

162. Brugiére O, Vokurka M, Lecossier D, Mangiapan G, Amrane A, Milleron B, Mayaud C, Cadranel J, Hance AJ. Diagnosis of smear-negative pulmonary tuberculosis using sequence capture polymerase chain reaction. *Am J Respir Crit Care Med* 1997; 155(4): 1478-81
163. Buck GE, O'Hara LC, Summersgill JT. Rapid, simple method for treating clinical specimens containing *Mycobacterium tuberculosis* to remove DNA for polymerase chain reaction. *J Clin Microbiol* 1992; 30:1331-34
164. Canbolat O, Ulusdoyuran S, Ozgen G, Ceyhan I, Gumuslu F, Akbay A. The comparison of adenosine deaminase activity values with polymerase chain reaction results in patients with tuberculosis. *J Clin Lab Anal* 1999; 13(5): 209-12
165. Cataloluk O, Karsligil T, Bayazit N. Evaluation of a polymerase chain reaction amplification method for *Mycobacterium tuberculosis* complex on samples from different sources. *Scand J Infect Dis* 2003; 35(5): 329-31
166. Chan CM, Yuen KY, Chan KS, Yam WC, Yim KH, Ng WF, Ng MH. Single-tube nested PCR in the diagnosis of tuberculosis. *J Clin Pathol* 1996; 49(4): 290-94
167. Chapin K, Lauderdale TL. Evaluation of rapid air thermal cycler for detection of *Mycobacterium tuberculosis*. *J Clin Microbiol* 1997; 35(8): 2157-59
168. Charoenratanakul S, Chaiprasert A, Yenchtsomanas P, Pattanakitsakul S, Jearanaisilavong J, Dejsomritrutai W. Clinical utility of the polymerase chain reaction in bronchoalveolar lavage in the diagnosis of smear negative pulmonary tuberculosis. *Thai J Tuberc Chest Dis* 1996; 17:1-9
169. Chen NH, Liu YC, Tsao TC, Wu TL, Hsieh MJ, Chuang ML, Huang CC, Kuo AJ, Chen MC, Yang CT. Combined bronchoalveolar lavage and polymerase chain reaction in the diagnosis of pulmonary tuberculosis in smear-negative patients. *Int J Tuberc Lung Dis* 2002; 6(4): 350-55
170. Cheng VC, Yam WC, Hung IF, Woo PC, Lau SK, Tang BS, Yuen KY. Clinical evaluation of the polymerase chain reaction for the rapid diagnosis of tuberculosis. *J Clin Pathol.* 2004; 57(3):281-5
171. Chierakul N, Anantasetagoon T, Chaiprasert A, Tingtoy N. Diagnostic value of gastric aspirate smear and polymerase chain reaction in smear-negative pulmonary tuberculosis. *Respirology* 2003; 8(4): 492-6
172. Cho SN, Van der Vliet GME, Park S, Baik SH, Kim SK, Chong Y, Kolk AHJ, Klatser PR, Kim JD. Colorimetric Microwell plate hybridization assay for detection of amplified *Mycobacterium tuberculosis* DNA from sputum samples. *J. Clin. Microbiol* 1995; 33(3): 752-54
173. Choi YJ, Hu Y, Mahmood A. Clinical significance of a polymerase chain reaction assay for the detection of *Mycobacterium tuberculosis*. *Am J Clin Pathol* 1996; 105(2): 200-04
174. Clarridge JE, Shawar RM, Shinik TM, Plikaytis BB. Large-scale use of polymerase chain reaction for detection of *Mycobacterium tuberculosis* in routine mycobacteriology laboratory. *J Clin Microbiol* 1993; 31: 2049-56
175. Cormican MG, Glennon M, Riain UN, Smith T, Flynn J, Gannon F. Evaluation of a PCR assay for detection of *Mycobacterium tuberculosis* in clinical specimens. *Diagn Microbiol Infect Dis* 1995; 22(4): 357-60
176. Cousins DV, Wilton SD, Francis BR, Gow BL. Use of polymerase chain reaction for rapid diagnosis of tuberculosis. *J Clin Microbiol* 1992; 30(1): 255-58
177. Dar L, Sharma SK, Bhanu NV, Broor S, Chakraborty M, Pande JN, Seth P. Diagnosis of pulmonary tuberculosis by polymerase chain reaction for MPB64 gene: an evaluation in a blind study. *Indian J Chest Dis Allied Sci* 1998; 40(1): 5-16
178. Del Portillo P, Murillo LA, Patarroyo ME. Amplification of a species-specific DNA fragment of *Mycobacterium tuberculosis* and its possible use in diagnosis. *J Clin Microbiol* 1991; 29(10): 2163-68
179. Del Portillo P, Thomas MC, Martinez E, Maranon C, Valladares B, Patarroyo ME, Carlos Lopez M. Multiprimer PCR system for differential identification of mycobacteria in clinical samples. *J Clin Microbiol* 1996; 34(2): 324-28
180. Desjardin LE, Chen Y, Perkins MD, Teixeira L, Cave MD, Eisenach KD. Comparison of the ABI 7700 system (TaqMan) and competitive PCR for quantification of IS6110 DNA in sputum during treatment of tuberculosis. *J Clin Microbiol* 1998; 36(7): 1964-68
181. Desjardin LE, Perkins MD, Wolski K, Haun S, Teixeira L, Chen Y, Johnson JL, Ellner JJ, Dietze R, Bates J, Cave MD, Eisenach KD. Measurement of sputum *Mycobacterium tuberculosis* messenger RNA as a surrogate for response to chemotherapy. *Am J Respir Crit Care Med* 1999; 160(1): 203-10

182. Drobniewski FA, Watterson SA, Wilson SM, Harris GS. A clinical, microbiological and economic analysis of a national service for the rapid molecular diagnosis of tuberculosis and rifampicin resistance in *Mycobacterium tuberculosis*. *J Med Microbiol* 2000; 49(3): 271-8
183. Drosten C, Panning M, Kramme S. Detection of *Mycobacterium tuberculosis* by real-time PCR using pan-mycobacterial primers and a pair of fluorescence resonance energy transfer probes specific for the *M. tuberculosis* complex. *Clin Chem* 2003; 49(10): 1659-61
184. Dubiley S, Mayorova A, Ignatova A, Kirillov E, Stepanshina V, Kolesnikov A, Shemyakin I. New PCR-based assay for detection of common mutations associated with rifampin and isoniazid resistance in *Mycobacterium tuberculosis*. *Clin Chem* 2005; 51(2): 447-50
185. Eisenach KD, Siffrord MD, Cave MD, Bates JH, Crawford JT. Detection of *Mycobacterium tuberculosis* in sputum samples using a polymerase chain reaction. *Am Rev Respir Dis* 1991; 144(5): 1160-63
186. Fang F, Xiang Z, Chen R. Establishment of a multiplex PCR system to diagnose tuberculosis and other bacterial infections. *J Tongji Med Univ* 2000; 20(4): 324-6
187. Fauville-Dufaux M, Vanfleteren B, De Witt L, Vincke JP, Van Vooren JP, Yates MD, Serruys E, Content J. Rapid detection of tuberculous and non-tuberculous mycobacteria by polymerase chain reaction amplification of a 162 bp DNA fragment from antigen 85. *Eur J Clin Microbiol Infect Dis* 1992; 11: 979-803
188. Fauville-Dufaux M, Waelbroeck A, De Mol P, Vanfleteren B, Levy J, Debusschere P, Farber CM. Contribution of the polymerase chain reaction to the diagnosis of tuberculous infections in children. *Eur J Pediatr* 1996; 155(2):106-11
189. Folgueira L, Delgado R, Palenque E, Noriega AR. Detection of *Mycobacterium tuberculosis* DNA in clinical sample by using a simple lysis method and polymerase chain reaction. *J Clin Microbiol* 1993; 31: 1019-21
190. Forbes BA, Hicks KE. Direct detection of *Mycobacterium tuberculosis* in respiratory specimens in a clinical laboratory by polymerase chain reaction. *J Clin Microbiol* 1993; 31(7): 1688-94
191. Garcia-Quintanilla A, Garcia L, Tudo G, Navarro M, Gonzales J, Jimenez de Anta MT. Single tube balanced heminested PCR for detecting *Mycobacterium tuberculosis* in smear negative samples. *J Clin Microbiol* 2000; 1166-69
192. Garcia-Quintanilla A, Gonzalez-Martin J, Tudo G, Espasa M, Jimenez de Anta MT. Simultaneous identification of *Mycobacterium* genus and *Mycobacterium tuberculosis* complex in clinical samples by 5'-exonuclease fluorogenic PCR. *J Clin Microbiol* 2002; 40(12): 4646-51
193. Gengvinij N, Pattanakitsakul SN, Chierakul N, Chaiprasert A. Detection of *Mycobacterium tuberculosis* from sputum specimens using one-tube nested PCR. *Southeast Asian J Trop Med Public Health* 2001; 32(1): 114-25
194. Ginesu F, Pirina P, Sechi LA, Molicotti P, Santoru L, Porcu L, Fois A, Arghittu P, Zanetti S, Fadda G. Microbiological diagnosis of tuberculosis: a comparison of old and new methods. *J Chemother* 1998; 10(4): 295-300
195. Gomez-Pastrana D, Torronteras R, Caro P, Anguita ML, Barrio AM, Andres A, Navarro J. Diagnosis of tuberculosis in children using a polymerase chain reaction. *Pediatr Pulmonol* 1999; 28(5): 344-51
196. Gori A, Franzetti F, Marchetti G, Catozzi L, Corbellino M. Specific detection of *Mycobacterium tuberculosis* by mtp40 nested PCR. *J Clin Microbiol* 1996; 34(11): 2866-67
197. Gunisha P, Madhavan HN, Jayanthi U, Therese KL. Polymerase chain reaction using IS6110 primer to detect *Mycobacterium tuberculosis* in clinical samples. *Indian J Pathol Microbiol* 2000; 43(4): 395-402
198. Hashimoto T, Suzuki K, Amitani R, Kuze F. Rapid detection of *Mycobacterium tuberculosis* in sputa by the amplification of IS6110. *Intern Med* 1995; 34(7): 605-10
199. Heginbotham ML, Magee JT, Flanagan PG. Evaluation of the Idaho Technology LightCycler PCR for the direct detection of *Mycobacterium tuberculosis* in respiratory specimens. *Int J Tuberc Lung Dis* 2003; 7(1): 78-83
200. Hellyer TJ, DesJardin LE, Hehman GL, Cave MD, Eisenach KD. Quantitative analysis of mRNA as a marker for viability of *Mycobacterium tuberculosis*. *J Clin Microbiol* 1999; 37(2): 290-5
201. Hellyer TJ, DesJardin LE, Teixeira L, Perkins MD, Cave MD, Eisenach KD. Detection of viable *Mycobacterium tuberculosis* by reverse transcriptase-strand displacement amplification of mRNA. *J Clin Microbiol* 1999; 37(3): 518-23

202. Hellyer TJ, Fletcher TW, Bates JH, Stead WW, Templeton GL, Cave MD, Eisenach KD. Strand displacement amplification and the polymerase chain reaction for monitoring response to treatment in patients with pulmonary tuberculosis. *J Infect Dis* 1996; 173(4): 934-41
203. Hernandez Abanto SM, Hirata MH, Hirata RD, Mamizuka EM, Schmal M, Hoshino-Shimizu S. Evaluation of Henes-PCR assay for *Mycobacterium* detection in different clinical specimens from patients with or without tuberculosis-associated HIV infection. *J Clin Lab Anal* 2000; 14(5): 238-45
204. Herrera EA, Segovia M. Evaluation of mtp40 genomic fragment amplification for specific detection of *Mycobacterium tuberculosis* in clinical specimens. *J Clin Microbiol* 1996; 34: 1108-13
205. Herrera-Leon L, Molina T, Saiz P, Saez-Nieto JA, Jimenez MS. New multiplex PCR for rapid detection of isoniazid-resistant *Mycobacterium tuberculosis* clinical isolates. *Antimicrob Agents Chemother* 2005; 49(1): 144-7
206. Heyderman RS, Goyal M, Roberts P, Ushewokunze S, Zizhou S, Marshall BG, Makombe R, Van Embden JD, Mason PR, Shaw RJ. Pulmonary tuberculosis in Harare, Zimbabwe: analysis by spoligotyping. *Thorax* 1998; 53(5): 346-50
207. Hidaka E, Honda T, Ueno I, Yamasaki Y, Kubo K, Katsuyama T. Sensitive identification of mycobacterial species using PCR-RFLP on bronchial washings. *Am J Respir Crit Care Med* 2000; 161: 930-34
208. Ikonomopoulos JA, Gorgoulis VG, Zacharatos PV, Kotsinas A, Tsoli E, Karameris A, Panagou P, Kittas C. Multiplex PCR assay for the detection of mycobacterial DNA sequences directly from sputum. *In Vivo* 1998; 12(5): 547-52
209. Inyaku K, Hiyama K, Ishioka S, Inamizu T, Yamakido M. Rapid detection and identification of mycobacteria in sputum samples by nested polymerase chain reaction and restriction fragment length polymorphisms of dnaJ heat shock protein gene. *Hiroshima J Med Sci* 1993; 42(1): 21-31
210. Issa R, Ayob H, Yasin RM. Detection of *Mycobacterium tuberculosis* in patients with HIV infection using PCR and nonradioactive detection system. *International Medical Journal* 1998; 5(4): 273-6
211. Jatana SK, Nair MN, Lahiri KK, Sarin NP. Polymerase chain reaction in the diagnosis of tuberculosis. *Indian Pediatr* 2000; 37(4): 375-82
212. Jou NT, Yoshimori RB, Mason GR, Louie JS, Liebling MR. Single-tube, nested, reverse transcriptase PCR for detection of viable *Mycobacterium tuberculosis*. *J Clin Microbiol* 1997; 35(5): 1161-65
213. Kadival GV, D'Souza CD, Kolk AH, Samuel AM. Polymerase chain reaction in the diagnosis of tuberculosis. Comparison of two target sequences for amplification. *Zentralbl Bakteriell* 1995; 282(4): 353-61
214. Kamerbeek J, Schouls I, Kolk A, Van Agterveld M, Van Soolingen D, Kuijper S, Bunschoten A, Molhuizen H, Shaw R, Goyal M, Van Embden J. Simultaneous detection and strain differentiation of *Mycobacterium tuberculosis* for diagnosis and epidemiology. *J Clin Microbiol* 1997; 35(4): 907-14
215. Kearns AM, Freeman R, Steward M. Evaluation of a rapid thermal cycler for detection of *Mycobacterium tuberculosis*. *J Clin Microbiol* 1998; 36(2): 604
216. Kennedy, N, Gillespie SH, Saruni AOS, Kisyombe G, McNerney G, Ngowi FI, Wilson S. Polymerase chain reaction for assessing treatment response in patients with pulmonary tuberculosis. *J Infect Dis* 1994; 170 : 713-16
217. Khandekar P, Amin A., Reddy PP, Banwalikar JN, Channapa, Shivannaure T, Katoch VM. Evaluation of PCR- based test for the detection of mycobacterium tuberculosis in coded sputum specimens. *Indian J Med Res* 1994; 100: 167-71
218. Kirschner P, Rosenau J, Springer B, Teschner K, Feldmann K, Bottger EC. Diagnosis of mycobacterial infections by nucleic acid amplification: 18-month prospective study. *J Clin Microbiol* 1996; 34(2): 304-12
219. Kocagoz T, Yilmaz E, Ozkara S, Kocagoz S, Hayran M, Sachedeva M, Chambers HF. Detection of *Mycobacterium tuberculosis* in sputum samples by polymerase chain reaction using a simplified procedure. *J Clin Microbiol* 1993; 31(6): 1435-38
220. Kolk AHJ, Schuitema ARJ, Kuijper S, VanLeeuwen J, Hermans PWM, Van Embden JDA, and Hartskeel RA. Detection of *Mycobacterium tuberculosis* in clinical samples by using polymerase chain reaction and a non-radioactive detection system. *J Clin Microbiol* 1992; 30: 2567-75



221. Kox LF, Jansen HM, Kuijper S, Kolk AH. Multiplex PCR assay for immediate identification of the infecting species in patients with mycobacterial disease. *J Clin Microbiol* 1997; 35(6): 1492-98
222. Kox LF, van Leeuwen J, Knijper S, Jansen HM, Kolk AH. PCR assay based on DNA coding for 16S rRNA for detection and identification of mycobacteria in clinical samples. *J Clin Microbiol* 1995; 33(12): 3225-33
223. Kox LFF, Rhienthong D, Medo Miranda AM, Udomsantisuk N, Ellis K, Van Leeuwen J, Van Heusden S, Kuijper S, Kolk AHJ. A more reliable PCR for detection of *Mycobacterium tuberculosis* in clinical sample. *J Clin Microbiol* 1994; 32: 672-78
224. Kraus G, Cleary T, Miller N, Seivright R, Young AK, Spruill G, Hnatyszyn HJ. Rapid and specific detection of the *Mycobacterium tuberculosis* complex using fluorogenic probes and real-time PCR *Mol Cell Probes* 2001; 15(6): 375-83
225. Lazraq R, el Baghdadi J, Guesdon JL, Benslimane A. Evaluation of IS6110 as amplification target for direct tuberculosis diagnosis. *Pathol Biol (Paris)* 1999; 47(8): 790-96
226. Levee G, Glaziou P, Gicquel B, Chanteau S. Follow-up of tuberculosis patients undergoing standard anti-tuberculosis chemotherapy by using a polymerase chain reaction. *Res Microbiol* 1994; 145(1): 5-8
227. Liam CK, Chen YC, Yap SF, Srinivas P, Poi PJ. Detection of *Mycobacterium tuberculosis* in bronchoalveolar lavage from patients with sputum smear-negative pulmonary tuberculosis using a polymerase chain reaction assay. *Respirology* 1998; 3(2): 125-29
228. Maher M, Glennon M, Martinazzo G, Turchetti E, Marcolini S, Smith T, Dawson MT. Evaluation of a novel PCR-based diagnostic assay for detection of *Mycobacterium tuberculosis* in sputum samples. *J Clin Microbiol* 1996; 34(9): 2307-8
229. Mangiapan G, Vokurka M, Schouls L, Cadranel J, Lecossier D, van Embden J, Hance A. Sequence capture-PCR improves detection of mycobacterial DNA in clinical specimens. *J Clin Microbiol* 1996; 34: 1209-15
230. Manjunath N, Shankar P, Rajan L, Bhargava A, Saluja S, Shrinivas. Evaluation of a polymerase chain reaction for the diagnosis of tuberculosis. *Tubercle* 1991; 72(1): 21-27
231. Marei AM, El-Behedy EM, Mohtady HA, Afify AF. Evaluation of a rapid bacteriophage-based method for the detection of *Mycobacterium tuberculosis* in clinical samples. *J Med Microbiol* 2003; 52(4): 331-335
232. Marin M, Garcia de Viedma D, Ruiz-Serrano MJ, Bouza E. Rapid direct detection of multiple rifampin and isoniazid resistance mutations in *Mycobacterium tuberculosis* in respiratory samples by real-time PCR. *Antimicrob Agents Chemother* 2004; 48(11): 4293-300
233. Mayta H, Gilman RH, Arenas F, Valencia T, Caviedes L, Montenegro SH, Ticona E, Ortiz J, Chumpitaz R, Evans CA, Williams DL. Evaluation of a PCR-Based Universal Heteroduplex Generator Assay As A Tool for Rapid Detection of Multidrug-Resistant *Mycobacterium tuberculosis* in Peru. *J Clin Microbiol* 2003; 41(12): 5774-77
234. Mitarai S, Oishi K, Fukasawa M, Yamashita H, Nagatake T, Matsumoto K. Clinical evaluation of polymerase chain reaction DNA amplification method for the diagnosis of pulmonary tuberculosis in patients with negative acid-fast bacilli smear. *Tohoku J Exp Med* 1995; 177(1): 13-23
235. Miyazaki K., Koga H, Kohno S, Kaku M. Nested polymerase chain reaction for detection of *Mycobacterium tuberculosis* in clinical samples. *J Clin Microbiol* 1993; 31: 2228-32
236. Montenegro SH, Gilman RH, Sheen P, Cama R, Caviedes L, Hopper T, Chambers R, Oberhelman RA. Improved detection of *Mycobacterium tuberculosis* in Peruvian children by use of a heminested IS6110 polymerase chain reaction assay. *Clin Infect Dis* 2003; 36(1): 16-23
237. Mustafa AS, Abal AT, Chugh TD. Detection of *Mycobacterium tuberculosis* complex and non-tuberculous mycobacteria by multiplex polymerase chain reactions. *East Mediterr Health J* 1999; 5(1): 61-70
238. Mustafa AS, Ahmed A, Abal AT, Chugh TD. Establishment and evaluation of a multiplex polymerase chain reaction for detection of mycobacteria and specific identification of *Mycobacterium tuberculosis* complex. *Tuber Lung Dis* 1995; 76(4): 336-43
239. Nastasi A, Mammìna C, Lucia DC. Contribution of nucleic acid amplification to diagnosis of pulmonary tuberculosis. *Ann Ig* 1997; 9(5): 347-52

240. Negi SS, Khan SF, Gupta S, Pasha ST, Khare S, Lal S. Comparison of the conventional diagnostic modalities, bactec culture and polymerase chain reaction test for diagnosis of tuberculosis. *Indian J Med Microbiol* 2005; 23(1): 29-33
241. Nolte FS, Metchock B, McGowan JE Jr, Edwards A, Okwumabua O, Thurmond C, Mitchell PS, Plikaytis B, Shinnick T. Direct detection of *Mycobacterium tuberculosis* in sputum by polymerase chain reaction and DNA hybridization. *J Clin Microbiol* 1993; 31(7): 1777-82
242. Noordhoek GT, Kaan JA, Mulder S, Wilke H, Kolk AHJ. Application of the polymerase chain reaction in a routine microbiology laboratory for detection of *Mycobacterium tuberculosis* in clinical samples. *J Clin Pathol* 1995; 48: 810-14
243. Palacios JJ, Ferro J, Telenti M, Roces SG, Prendes P, Garcia JM, Nicolas AI, Rodrigues J, Villar H, de Quiros JF. Comparison of solid and liquid culture media with polymerase chain reaction for detection of *Mycobacterium tuberculosis* in clinical samples. *Eur J Clin Microbiol Infect Dis* 1996; 15(6): 478-83
244. Palenque E, Rebollo MJ, Garcia-Bravo M, Aguado JM. Polymerase chain reaction for assessing treatment response in patients with pulmonary tuberculosis. *J Infect Dis* 1995; 172(2): 608-9
245. Pao CC, Benedict Yen TS, You JB, Maa JS, Fiss EH, Chang CH. Detection and identification of *Mycobacterium tuberculosis* by DNA amplification. *J. Clin Microbiol* 1990; 28:1877-80
246. Parvez MA, Hasan KN, Rumi MA, Ahmed S, Salimullah M, Tahera Y, Gomes DJ, Huq F, Hassan MS. PCR can help early diagnosis of pulmonary tuberculosis. *Southeast Asian J Trop Med Public Health* 2003; 34(1): 147-53
247. Patnaik M, Liegmann K, Peter JB. Rapid detection of smear-negative *Mycobacterium tuberculosis* by PCR and sequencing for rifampin resistance with DNA extracted directly from slides. *J Clin Microbiol* 2001; 39(1): 51-52
248. Perera J, Chandrasekharan NV, Karunanayake EH. PCR based detection of *Mycobacterium tuberculosis*: effect of sample preparation. *Southeast Asian J Trop Med Public Health* 1994; 25(4): 693-7
249. Pierre C, Lecossier D, Boussougant Y, Bocart D, Joly V, Yeni P, Hance AJ. Use of a reamplification protocol improves sensitivity of detection of *Mycobacterium tuberculosis* in clinical sample by amplification of DNA. *J Clin Microbiol* 1991; 29: 712-17
250. Pietrzak J, Frei R, Senn P, Moroni C. Comparison of polymerase chain reaction with standard methods in the diagnosis of mycobacterium tuberculosis infection. *Eur J Clin Microbiol Infect Dis* 1994; 13: 1079-83
251. Querol JM, Farga MA, Granda D, Gimeno C, Garcia-de-Lomas J. The utility of polymerase chain reaction (PCR) in the diagnosis of pulmonary tuberculosis. *Chest* 1995;107(6): 1631-35
252. Ranganathan I, Menon MM. Evaluation of various modalities for the diagnosis of tuberculosis in body fluids. *Indian J Pathol Microbiol* 1999; 42(4): 435-39
253. Reischl U, Pulz M, Ehret W, Wolf H. PCR-based detection of mycobacteria in sputum samples using a simple and reliable DNA extraction protocol. *Biotechniques* 1994;17(5):844-5
254. Rindi L, Bianchi L, Tortoli E, Lari N, Bonanni D, Garzelli C. A real-time PCR assay for detection of isoniazid resistance in *Mycobacterium tuberculosis* clinical isolates. *J Microbiol Methods* 2003; 55(3): 797-800
255. Ritis K, Tzoanopoulos D, Speletas M, Papadopoulos E, Arvanitidis K, Kartali S, Sideras P. Amplification of IS6110 sequence for detection of *Mycobacterium tuberculosis* complex in HIV-negative patients with fever of unknown origin (FUO) and evidence of extrapulmonary disease. *J Intern Med* 2000; 248(5): 415-24
256. Rodriguez JC, Fuentes E, Royo G. Comparison of two different PCR detection methods. Application to the diagnosis of pulmonary tuberculosis. *APMIS* 1997; 105(8): 612-16
257. Rossetti MLR, Jardim SB, De FS Rodrigues V, Moura AR, Oliveira H, Zaha A. Improvement of *Mycobacterium tuberculosis* detection in clinical samples using DNA purified by glass matrix. *J Microbiol Methods* 1997; 28(2) : 139-146
258. Rossi MC, Gori A, Zehender G, Marchetti G, Ferrario G, De Maddalena C, Catozzi L, Bandera A, Esposti AD, Franzetti F. A PCR-colorimetric microwell plate hybridization assay for detection of *Mycobacterium tuberculosis* and *M. avium* from culture samples and Ziehl-Neelsen-positive smears. *J Clin Microbiol* 2000; 38(5): 1772-76
259. Ruiz M, Torres MJ, Llanos AC, Arroyo A, Palomares JC, Aznar J. Direct detection of rifampin and isoniazid-resistant *Mycobacterium tuberculosis* in auramine-rhodamine-positive sputum specimens by real-time PCR. *J Clin Microbiol* 2004; 42(4): 1585-9

260. Savic B, Sjobring U, Larsson L, Miorner H. Evaluation of polymerase chain reaction, tuberculostearic acid analysis, and direct microscopy for the detection of *Mycobacterium tuberculosis* in sputum. *J Infect Dis* 1992;166(5):1177-80
261. Schijman AG, Losso MH, Montoto M, Saez CB, Smayevsky J, Benetucci JA. Prospective evaluation of in-house polymerase chain reaction for diagnosis of mycobacterial diseases in patients with HIV infection and lung infiltrates. *Int J Tuberc Lung Dis* 2004; 8(1): 106-113
262. Schluger NW, Kinney D, Harkin TJ, Rom WN. Clinical utility of the polymerase chain reaction in the diagnosis of infections due to *Mycobacterium tuberculosis*. *Chest* 1994; 105(4): 1116-21
263. Sechi LA, Pinna MP, Sanna A, Pirina P, Ginesu F, Saba F, Aceti A, Turrini F, Zanetti S, Fadda G. Detection of *Mycobacterium tuberculosis* by PCR analysis of urine and other clinical samples from AIDS and non-HIV-infected patients. *Mol Cell Probes* 1997; 11(4): 281-85
264. Seethalakshmi S, Korath MP, Kareem F, Jagadeesan K. Detection of *Mycobacterium tuberculosis* by polymerase chain reaction in 301 biological samples--a comparative study. *J Assoc Physicians India* 1998; 46(9): 763-6
265. Shankar P, Manjunath N, Lakshmi R, Aditi B, Seth P, Shriniwas. Identification of *Mycobacterium tuberculosis* by polymerase chain reaction. *Lancet* 1990; 335(8686):423
266. Shawar RM, El-Zaatari FAK, Nataraj A, Clarridge JE. Detection of mycobacterium tuberculosis in clinical samples by two-step polymerase chain reaction and nonisotopic hybridization methods. *J Clin Microbiol* 1993; 31: 61-65
267. Shim JJ, Cheong HJ, Kang EY, In KH, Yoo SH, Kang KH. Nested polymerase chain reaction for detection of *Mycobacterium tuberculosis* in solitary pulmonary nodules. *Chest* 1998; 113(1): 20-4
268. Shim MS, Lee SY, Cho SH, Park YK, Bai GH, Kim SJ. Efficiency of different primers in polymerase chain reaction to detect *Mycobacterium tuberculosis* in clinical specimens. *J Kor Soc Microbiol* 1993; 28: 391-5
269. Shrestha NK, Tuohy MJ, Hall GS, Reischl U, Gordon SM, Procop GW. Detection and differentiation of *Mycobacterium tuberculosis* and nontuberculous mycobacterial isolates by real-time PCR. *J Clin Microbiol* 2003; 41(11):5121-6
270. Shrestha NK, Tuohy MJ, Hall GS, Reischl U, Gordon SM, Procop GW. Detection and differentiation of *Mycobacterium tuberculosis* and nontuberculous mycobacterial isolates by real-time PCR. *J Clin Microbiol* 2003; 41(11): 5121-6
271. Sjobring U, Mecklenburg M, Andersen AB, Miorner H. Polymerase chain reaction for detection of *Mycobacterium tuberculosis*. *J Clin Microbiol* 1990; 29: 2200-04
272. Skotnikova OI, Sobolev AY, Demkin VV, Nikolaeva NP, Nosova EY, Isaeva EL, Moroz AM, Litvinov VI. Application of nested-PCR technique for the diagnosis of tuberculosis. *Bull Exp Biol Med* 2000;129(6):612-4
273. Smith KC, Starke JR, Eisenach K, Ong LT, Denby M. Detection of *Mycobacterium tuberculosis* in clinical specimens from children using a polymerase chain reaction. *Pediatrics* 1996; 97(2): 155-60
274. Soini H, Skurnik M, Liippo K, Tala E, Viljanen MK. Detection and identification of mycobacteria by amplification of a segment of the gene coding for the 32-kilodalton protein. *J. Clin Microbiol* 1992; 30: 2025-28
275. Sperhake RD, Mello FC, Zaha A, Kritski A, Rossetti ML. Detection of *Mycobacterium tuberculosis* by a polymerase chain reaction colorimetric dot-blot assay. *Int J Tuberc Lung Dis* 2004; 8(3): 312-7
276. Sritharan V, Barker RH. A simple method for diagnosing *M. Tuberculosis* infection in clinical sample using PCR. *Mol Cell Probes* 1991; 5: 385-95
277. Su WJ, Tsou AP, Yang MH, Huang CY, Perng RP. Clinical experience in using polymerase chain reaction for rapid diagnosis of pulmonary tuberculosis. *Chin Med J (Taipei)* 2000; 63(7): 521-6
278. Taci N, Yurdakul AS, Ceyhan I, Berktaş MB, Ogretensoy M. Detection of *Mycobacterium tuberculosis* DNA from peripheral blood in patients with HIV-seronegative and new cases of smear-positive pulmonary tuberculosis by polymerase chain reaction. *Respir Med* 2003; 97(6): 676-81
279. Tan J, Lee BW, Lim TK, Chin NK, Tan CB, Xia JR, Yap HK, Kumarasinghe G. Detection of *Mycobacterium tuberculosis* in sputum, pleural and bronchoalveolar lavage fluid using DNA amplification of the MPB 64 protein coding gene and IS6110 insertion element. *Southeast Asian J Trop Med Public Health* 1995; 26(2): 247-52

280. Tan MF, Ng WC, Chan SH, Tan WC. Comparative usefulness of PCR in the detection of *Mycobacterium tuberculosis* in different clinical specimens. *J Med Microbiol* 1997; 46(2): 164-69
281. Tan YK, Lee AS, Khoo KL, Ong SY, Wong SY, Ong YY. Rapid mycobacterial tuberculosis detection in bronchoalveolar lavage samples by polymerase chain reaction in patients with upper lobe infiltrates and bronchiectasis. *Ann Acad Med Singapore* 1999; 28(2): 205-8
282. Tanaka II, Anno IS, Leite SR, Cooksey RC, Leite CQ. Comparison of a multiplex-PCR assay with mycolic acids analysis and conventional methods for the identification of mycobacteria. *Microbiol Immunol* 2003; 47(5): 307-12
283. Tang YW, Meng S, Li H, Stratton CW, Kayamatsu T, Zheng X. PCR enhances acid-fast bacillus stain-based rapid detection of *Mycobacterium tuberculosis*. *J Clin Microbiol* 2004; 42(4): 1849-50
284. Tansuphasiri U, Boonrat P, Rienthong S. Direct identification of *Mycobacterium tuberculosis* from sputum on Ziehl-Neelsen acid fast stained slides by use of silica-based filter combined with polymerase chain reaction assay. *J Med Assoc Thai* 2004; 87(2):180-9
285. Tansuphasiri U, Chinrat B, Rienthong S. Evaluation of culture and PCR-based assay for detection of *Mycobacterium tuberculosis* from sputum collected and stored on filter paper. *Southeast Asian J Trop Med Public Health* 2001; 32(4): 844-55
286. Tansuphasiri U. Detection of *Mycobacterium tuberculosis* from sputum collected on filter paper and stored at room temperature for 5 days by PCR assay and culture. *J Med Assoc Thai* 2001; 84(8): 1183-9
287. Thierry D, Brisson-Noel A, Vincent-Levy Frebault V, Nguyen S, Guesdon JL, Gicquel B. Characterization of a *Mycobacterium tuberculosis* insertion sequence, IS6110, and its application in diagnosis. *J Clin Microbiol* 1990; 28: 2668-73
288. Thierry D, Chureau C, Aznar C, Guesdon JL. The detection of *M. tuberculosis* in uncultured clinical specimens using the polymerase chain reaction and a non-radioactive probe. *Mol Cell Probes* 1992; 6: 181-91
289. Tiwari V, Jain A, Verma RK. Application of enzyme amplified mycobacterial DNA detection in the diagnosis of pulmonary & extra-pulmonary tuberculosis. *Indian J Med Res* 2003; 118:224-8
290. Torres MJ, Criado A, Ruiz M, Llanos AC, Palomares JC, Aznar J. Improved real-time PCR for rapid detection of rifampin and isoniazid resistance in *Mycobacterium tuberculosis* clinical isolates. *Diagn Microbiol Infect Dis* 2003; 45(3): 207-212
291. Totsch M, Schmid KW, Brommelkamp E, Stucker A, Puelacher C, Sidoroff G, Mikuz G, Bocker W, Dockhorn-Dworniczak B. Rapid detection of mycobacterial DNA in clinical samples by multiplex PCR. *Diagn Mol Pathol* 1994; 3(4): 260-4
292. Tumwasorn S, Kwanlertjit S, Mokmued S, Charoenlap P. Comparison of DNA targets for amplification by polymerase chain reaction for detection of *Mycobacterium tuberculosis* in sputum. *J Med Assoc Thai* 1996; 79 Suppl 1: S113-8
293. Vago L, Zerbi P, Caldarelli-Stefano R, Cannone M, D'Amico M, Bonetto S, Barberis M. Polymerase chain reaction for *Mycobacterium tuberculosis* complex DNA. Use on negative archival Ziehl-Neelsen cytologic samples. *Acta Cytol* 2000; 44(6): 1023-8
294. Van Doorn HR, Claas ECJ, Templeton KE, Van der Zanden AGM, Te Koppele Vije A, De Jong MD, Dankert J, Kuijper EJ. Detection of a point mutation associated with high-level isoniazid resistance in *Mycobacterium tuberculosis* by using real-time PCR technology with 3'-minor groove binder-DNA probes. *J Clin Microbiol* 2003; 41(10): 4630-35
295. Van Helden PD, Du Toit R, Jordaan A, Taljaard B, Pitout J, Victor T. The use of the Polymerase Chain reaction test in the diagnosis of tuberculosis. *South African Med J* 1991; 80: 515-16
296. Veringa E, Van Harsselaar B, Hermans P. Polymerase chain reaction to detect *Mycobacterium tuberculosis* in a clinical microbiology laboratory. *J Microbiol Methods* 1993; 17(2): 165
297. Verma A, Rattan A, Tyagi JS. Development of a 23S rRNA-based PCR assay for the detection of mycobacteria. *Indian J Biochem Biophys* 1994; 31(4): 288-94
298. Victor T, Du Toit R, Van Helden PD. Purification of sputum samples through sucrose improves detection of *Mycobacterium tuberculosis* by polymerase chain reaction. *J Clin Microbiol* 1992; 30: 1514-17
299. Walker DA, Taylor IK, Mitchell DM, Shaw RJ. Comparison of polymerase chain reaction amplification of two mycobacterial DNA sequences, IS6110 and the 65kDa antigen gene in the diagnosis of tuberculosis. *Thorax* 1992; 47: 690-94

300. Wang SW, Hsieh SC, Ding MJ. Rapid detection of *Mycobacterium tuberculosis* in various clinical specimens by using polymerase chain reaction combined with a nonradioactive hybridization system. *Chin J Microbiol Immunol* 1997; 30(3): 160-69
301. Watterson SA, Wilson SM, Yates MD, Drobniowski FA. Comparison of three molecular assays for rapid detection of rifampin resistance in *Mycobacterium tuberculosis*. *J Clin Microbiol* 1998; 36(7): 1969-73
302. Weekes KM, Pearse MJ, Sievers A, Ross BC, d'Apice AJ. The diagnostic use of the polymerase chain reaction for the detection of *Mycobacterium tuberculosis*. *Pathology* 1994; 26(4): 482-86
303. Wilson SM, McNerney R, Nye PM, Godfrey-Faussett PD, Stoker NG, Voller A. Progress toward a simplified polymerase chain reaction and its application to diagnosis of tuberculosis. *J Clin Microbiol* 1993; 31: 776-82
304. Wilson SM, Nava E, Morales A, Godfrey-Faussett P, Gillespie S, Andersson N. Simplification of the polymerase chain reaction for detection of *Mycobacterium tuberculosis* in the tropics. *Trans R Soc Trop Med Hyg* 1993; 87(2): 177-80
305. Wong CF, Yew WW, Chan CY, Au LY, Cheung SW, Cheng AF. Rapid diagnosis of smear-negative pulmonary tuberculosis via fiberoptic bronchoscopy: utility of polymerase chain reaction in bronchial aspirates as an adjunct to transbronchial biopsies. *Respir Med* 1998; 92(6):815-19
306. Yoon KH, Cho SN, Lee TY, Cheon SH, Chang J, Kim SK, Chong Y, Chung DH, Lee WY, Kim JD. Detection of *Mycobacterium tuberculosis* in clinical samples from patients with tuberculosis or other pulmonary diseases by polymerase chain reaction. *Yonsei Med J* 1992; 33(3): 209-16
307. Yuen KY, Chan KS, Chan CM, Ho BS, Dai LK, Chau PY, Ng MH. Use of PCR in routine diagnosis of treated and untreated pulmonary tuberculosis. *J Clin Pathol* 1993; 46(4): 318-22
308. Yuen KY, Chan KS, Chan CM, Ho PL, Ng MH. Monitoring the therapy of pulmonary tuberculosis by nested polymerase chain reaction assay. *J Infect* 1997; 34(1): 29-33
309. Zambardi G, Druetta A, Roure C, Fouqué B, Girardo P, Chypre C, Marchand J, Freney J, Fleurette J. Rapid diagnosis of *Mycobacterium tuberculosis* infections by an ELISA-like detection of polymerase chain reaction products. *Mol Cell Probes* 1995; 9: 91-99
310. Zhou AT, Ma WL, Zhang PY, Cole RA. Detection of pulmonary and extrapulmonary tuberculosis patients with the 38-kilodalton antigen from *Mycobacterium tuberculosis* in a rapid membrane-based assay. *Clin Diagn Lab Immunol* 1996; 3(3): 337-41
311. An Q, Buxton D, Hendricks A, Robinson L, Shah J, Lu L, Vera-Garcia M, King W, Olive M. Comparison of amplified Q-replicase and PCR assays for detection of *Mycobacterium tuberculosis*. *J Clin Microbiol* 1995; 33: 860-867
312. Bergmann JS, Woods GL. Clinical evaluation of the BDProbeTec strand displacement amplification assay for rapid diagnosis of tuberculosis. *J Clin Microbiol* 1998;36(9):2766-68
313. Bodmer T., A. Gurtner, K. Schopfer, Matter L. Screening of respiratory tract specimens for the presence of *Mycobacterium tuberculosis* by using the Gen-Probe Amplified *Mycobacterium Tuberculosis* Direct Test. *J Clin Microbiol* 1994; 32: 1483-87
314. Bradley SP, Reed SL, Catanzaro A. Clinical efficacy of the amplified *Mycobacterium tuberculosis* direct test for the diagnosis of pulmonary tuberculosis. *Am J Respir Crit Care Med*. 1996; 153(5):1606-10
315. Down JA, O'Connell MA, Dey MS, Walters AH, Howard DR, Little MC, Keating WE, Zwadyk P Jr, Haaland PD, McLaurin DA 3rd, Cole G. Detection of *Mycobacterium tuberculosis* in respiratory specimens by strand displacement amplification of DNA. *J Clin Microbiol* 1996; 34(4): 860-65
316. Fairfax MR. Evaluation of the Gen-Probe Amplified *M. tuberculosis* direct detection Test. *Am J Clin Pathol* 1996; 106: 594-99
317. Gamboa F, Manterola JM, Lonca J, Vinado B, Matas L, Gimenez M, Manzano JR, Rodrigo C, Cardona PJ, Padilla E, Dominguez J, Ausina V. Rapid detection of *Mycobacterium tuberculosis* in respiratory specimens, blood and other non-respiratory specimens by amplification of rRNA. *Int J Tuberc Lung Dis* 1997;1(6):542-55
318. Hoffner SE, Cristea M, Klintz L, Petrini B, Kallenius G. RNA amplification for direct detection of *mycobacterium tuberculosis* in respiratory samples. *Scand J Infect Dis* 1996; 28(1): 59-61
319. Hoffner SE, Norberg R, Carlos Toro J, Winqvist N, Koivula T, Dias F, Svenson SB, Kallenius G. Direct detection of *Mycobacterium tuberculosis* in sputum samples from Guinea Bissau by an rRNA target-amplified test system. *Tuber Lung Dis* 1996; 77(1): 67-70

320. Jonas V, Alden MJ, Curry JI, Kamisango K, Knott CA, Landford R, Wolfe JM, Moore DF. Detection and identification of *Mycobacterium tuberculosis* directly from sputum sediments by amplification of rRNA. *J Clin Microbiol* 1993; 31: 2410-16
321. Jorgensen JH, Salinas JR, Paxson R, Magnon K, Patterson JE, Patterson TF. False-positive Gen-Probe direct *Mycobacterium tuberculosis* amplification test results for patients with pulmonary *M. kansasii* and *M. avium* infections. *J Clin Microbiol* 1999; 37(1): 175-78
322. La Rocco MT, Wanger A, Ocera H, Macias E. Evaluation of a commercial rRNA amplification assay for direct detection of *Mycobacterium tuberculosis* in processed sputum. *Eur J Clin Microbiol Infect Dis* 1994; 13: 726-31
323. Manterola JM, Gamboa F, Ionca J, Matas L, Ruiz Manzano J, Rodrigo C, Ausina V. Inhibitory effect of sodium dodecyl sulphate in detection of *Mycobacterium tuberculosis* by amplification of rRNA. *J Clin Microbiol* 1995; 33 (12): 3338-40
324. Miller N, Hernandez SG, Cleary TJ. Evaluation of Gen-Probe Amplified *Mycobacterium Tuberculosis* Direct Test and PCR for direct detection of *Mycobacterium tuberculosis* in clinical specimens. *J Clin Microbiol* 1994; 32(2): 393-97
325. Pfyffer GE, Funke-Kissling P, Rundler E, Weber R. Performance characteristics of the BDProbeTec system for direct detection of *Mycobacterium tuberculosis* complex in respiratory specimens. *J Clin Microbiol* 1999; 37(1):137-40
326. Pfyffer GE, Kissling P, Jahn EM, Welscher HM, Salfinger M, Weber R. Diagnostic performance of amplified *Mycobacterium tuberculosis* direct test with cerebrospinal fluid, other nonrespiratory, and respiratory specimens. *J Clin Microbiol* 1996; 34(4): 834-41
327. Pfyffer, GE, Kissling P, Wirth R, Weber R. Direct detection of *Mycobacterium tuberculosis* complex in respiratory specimens by a target-amplified test system. *J Clin Microbiol* 1994; 32: 918-23
328. Portaels F, Serruys E, De Beenhouwer H, Degraux J, De Ridder K, Fissette K, Gomez-Marin J, Goossens H, Muhlberger F, Pattyn SR, Nturyane F, Pouthier F, Van Deun A. Evaluation of the Gen-Probe amplified *Mycobacterium tuberculosis* direct test for the routine diagnosis of pulmonary tuberculosis. *Acta Clin Belg* 1996;51(3):144-49
329. Putova I, Havelkova M, Svandova E. Application of the Gen-Probe amplified MTD test (*Mycobacterium tuberculosis* Direct Test) in the diagnostics of tuberculosis. *Cent Eur J Public Health* 1996;4(2):91-5
330. Shah SJ, Liu J, Buxton D, Hendricks A, Robinson L., Radcliffe G, King W, Lane D, Olive DM, Klinger JD. Q-Beta Replicase-Amplified Assay for detection of *Mycobacterium tuberculosis* directly from clinical specimens. *J Clin Microbiol* 1995; 33: 1435-41
331. Smith JH, Buxton D, Cahill P, Fiandaca M, Goldston L, Marselle L, Rigby S, Olive DM, Hendricks A, Shimei T, Klinger JD, Lane DJ, Mahan DE. Detection of *Mycobacterium tuberculosis* directly from sputum by using a prototype automated Q-beta replicase assay. *J Clin Microbiol* 1997; 35(6): 1477-83
332. Smith JH, Radcliffe G, Rigby S, Mahan D, Lane DJ, Klinger JD. Performance of an automated Q-beta replicase amplification assay for *M.tuberculosis* in a clinical trial. *J Clin Microbiol* 1997; 35: 1484-91
333. Thomsen VO. Diagnosis of pulmonary tuberculosis. Application of gen-probe amplified *Mycobacterium tuberculosis* direct test. *APMIS* 1998; 106(7): 699-703
334. Vlassembler, Singer and Roggeveen. Diagnostic value of an amplification method (Gen-Probe) compared with that of culture for diagnosis of tuberculosis. *J Clin Microbiol* 1995; 33: 2699-703
335. Welch K, Brown G, Jonas V, Ferraro MJ. Performance of the Gen-Probe amplified *Mycobacterium tuberculosis* direct test in a laboratory that infrequently isolates *Mycobacterium tuberculosis*. *Diagn Microbiol Infect Dis* 1995; 22(3): 297-9
336. Alonso P, Orduna A, Bratos MA, San Miguel A, Rodriguez Torres A. Clinical evaluation of a commercial ligase-based gene amplification method for detection of *Mycobacterium tuberculosis*. *Eur J Clin Microbiol Infect Dis* 1998; 17(6): 371-76
337. Carpentier E, Drouillard B, Dailloux M, Moinard D, Vallee E, Dutilh B, Maugein J, Bergogne-Berezin E, Carbonnelle B. Diagnosis of tuberculosis by Amplicor *Mycobacterium tuberculosis* test: a multicenter study. *J Clin Microbiol* 1995; 33(12): 3106-10
338. Conaty SJ, Claxton AP, Enoch DA, Hayward AC, Lipman MC, Gillespie SH. The interpretation of nucleic acid amplification tests for tuberculosis: do rapid tests change treatment decisions? *J Infect* 2005; 50(3): 187-92



339. Eing BR, Becker A, Sohns A, Ringelmann R. Comparison of Roche Cobas Amplicor Mycobacterium tuberculosis assay with in-house PCR and culture for detection of M. tuberculosis. *J Clin Microbiol* 1998; 36(7): 2023-29
340. Lindbrathen A, Gaustad P, Hovig B, Tonjum T. Direct detection of Mycobacterium tuberculosis complex in clinical samples from patients in Norway by ligase chain reaction. *J Clin Microbiol* 1997; 35(12): 3248-53
341. Oh EJ, Park YJ, Chang CL, Kim BK, Kim SM. Improved detection and differentiation of mycobacteria with combination of Mycobacterium Growth Indicator Tube and Roche COBAS AMPLICOR System in conjunction with Duplex PCR. *J Microbiol Methods*. 2001; 46(1): 29-36
342. Se Thoe SY, Tay L, Sng EH. Evaluation of Amplicor- and IS6110-PCR for direct detection of Mycobacterium tuberculosis complex in Singapore. *Trop Med Int Health* 1997; 2(11): 1095-101
343. Shah S, Miller A, Mastellone A, Kim K, Colaninno P, Hochstein L, D'Amato R. Rapid diagnosis of tuberculosis in various biopsy and body fluid specimens by the AMPLICOR Mycobacterium tuberculosis polymerase chain reaction test. *Chest* 1998; 113(5): 1190-94
344. Shetty N, Shemko M, Holton J, Scott GM. Is the detection of Mycobacterium tuberculosis DNA by ligase chain reaction worth the cost: experiences from an inner London teaching hospital. *J Clin Pathol* 2000; 53(12): 924-28
345. Shibuya Y, Shiozaki T, Hayashi M, Sugiyama Y. Efficacy of Amplicor PCR for the diagnosis of tuberculosis in respiratory specimens other than sputum. *Tuber Lung Dis* 2000; 80(4-5): 209-15
346. Stauffer F, Haber H, Rieger A, Mutschlechner R, Hasenberger P, Tevere VJ, Young KK. Genus level identification of mycobacteria from clinical specimens by using an easy-to-handle Mycobacterium-specific PCR assay. *J Clin Microbiol* 1998; 36(3): 614-17
347. Visca P, De Mori P, Festa A, Montrone ML, Amicosante M, Pucillo LP. Evaluation of the BDProbeTec strand displacement amplification assay in comparison with the AMTD II direct test for rapid diagnosis of tuberculosis. *Clin Microbiol Infect* 2004; 10(4): 332-4
348. Wiener RS, Della-Latta P, Schluger NW. Effect of nucleic acid amplification for Mycobacterium tuberculosis on clinical decision making in suspected extrapulmonary tuberculosis. *Chest*. 2005; 128(1): 102-7
349. Wobeser WL, Kraiden M, Conly J, Simpson H, Yim B, D'costa M, Fuxsa M, Hian-Cheong C, Patterson M, Phillips A, Bannatyne R, Haddad A, Brunton JL, Kraiden S. Evaluation of Roche Amplicor PCR assay for Mycobacterium tuberculosis. *J Clin Microbiol* 1996; 34(1): 134-39
350. Yam WC, Cheng VC, Hui WT, Wang LN, Seto WH, Yuen KY. Direct detection of Mycobacterium tuberculosis in clinical specimens using single-tube biotinylated nested polymerase chain reaction-enzyme linked immunoassay (PCR-ELISA). *Diagn Microbiol Infect Dis* 2004; 48(4): 271-5
351. Delacourt C, Poveda JD, Chureau C, Beydon N, Mahut B, de Blic J, Scheinmann P, Garrigue G. Use of polymerase chain reaction for improved diagnosis of tuberculosis in children. *J Pediatr* 1995; 126(5 Pt 1): 703-9
352. Devallois A, Legrand E, Rastogi N. Evaluation of Amplicor MTB test as adjunct to smears and culture for direct detection of Mycobacterium tuberculosis in the French Caribbean. *J Clin Microbiol* 1996;34(5):1065-8
353. Gomez-Pastrana D, Torronteras R, Caro P, Anguita ML, Lopez-Barrio AM, Andrei A, Navarro J. Comparison of Amplicor, in-house polymerase chain reaction and conventional culture for the diagnosis of tuberculosis in children. *Clin Infect Dis* 2001; 32(1): 17-22
354. Jouveshomme S, Cambau E, Trystram D, Szpytma M, Sougakoff W, Derenne JP, Grosset J. Clinical utility of an amplification test based on ligase chain reaction in pulmonary tuberculosis. *Am J Respir Crit Care Med* 1998; 158(4): 1096-101
355. Neu N, Saiman L, San Gabriel P, Whittier S, Knirsch C, Ruzal-Shapiro C, Della-Latta P. - Diagnosis of pediatric tuberculosis in the modern era. *Pediatr Infect Dis J* 1999; 18(2): 122-26
356. Pierre C, Olivier C, Lecossier D, Boussougant Y, Yeni P, Hance AJ. Diagnosis of primary tuberculosis in children by amplification and detection of mycobacterial DNA. *Am Rev Respir Dis* 1993; 147(2): 420-4
357. Piersimoni C, Zitti P, Cimarelli ME, Nista D, De Sio G. Clinical utility of the Gen-Probe amplified Mycobacterium tuberculosis direct test compared with smear and culture for the diagnosis of pulmonary tuberculosis. *Clin Microbiol Infect* 1998; 4: 442-446
358. Moore DF, Curry JI, Knott CA, Jonas VI. Amplification of rRNA for assessment of treatment response of pulmonary tuberculosis patients during antimicrobial therapy. *J Clin Microbiol* 1996; 34: 1745-49

359. Rajalahti I, Vuorinen P, Liippo K, Nieminen MM, Miettinen A. Evaluation of commercial DNA and rRNA amplification assays for assessment of treatment outcome in pulmonary tuberculosis patients. *Eur J Clin Microbiol Infect Dis* 2001; 20(10): 746-50
360. Yajko DM, Wagner C, Tevere VJ, Kocagoz T, Hadley WK, Chambers HF. Quantitative culture of *Mycobacterium tuberculosis* from clinical sputum specimens and dilution endpoint of its detection by the Amplicor PCR assay. *J Clin Microbiol* 1995; 33(7): 1944-47
361. Dowdy DW, Maters A, Parrish N, Beyrer C, Dorman SE. Cost-effectiveness analysis of the gen-probe amplified mycobacterium tuberculosis direct test as used routinely on smear-positive respiratory specimens. *J Clin Microbiol* 2003; 41(3): 948-53
362. Lim TK, Cherian J, Poh KL, Leong TY. The rapid diagnosis of smear-negative pulmonary tuberculosis: a cost-effectiveness analysis. *Respirology* 2000; 5(4): 403-9
363. Maekura R, Kohno H, Hirotsu A, Okuda Y, Ito M, Ogura T, Yano I. Prospective clinical evaluation of the serologic tuberculous glycolipid test in combination with the nucleic acid amplification test. *J Clin Microbiol* 2003; 41(3): 1322-25
364. Mitarai S, Kurashima A, Tamura A, Nagai H, Shishido H. Clinical evaluation of Amplicor *Mycobacterium* detection system for the diagnosis of pulmonary mycobacterial infection using sputum. *Tuberculosis (Edinb)* 2001; 81(5-6): 319-25
365. Ridderhof JC, Williams LO, Legois S, Shult PA, Metchock B, Kubista LN, Handsfield JH, Fehd RJ, Robinson PH. Assessment of Laboratory Performance of Nucleic Acid Amplification Tests for Detection of *Mycobacterium tuberculosis*. *J Clin Microbiol* 2003; 41(11): 5258-61
366. Sarmiento OL, Weigle KA, Alexander J, Weber DJ, Miller WC. Assessment by meta-analysis of PCR for diagnosis of smear-negative pulmonary tuberculosis. *J Clin Microbiol* 2003; 41(7): 3233-40
367. Shim TS, Chi HS, Lee SD, Koh Y, Kim WS, Kim DS, Kim WD. Adequately washed bronchoscope does not induce false positive amplification tests on bronchial aspirates in the diagnosis of tuberculosis. *Chest* 2002; 121: 774-781
368. Sloutsky A, Han LL, Werner BG. New method for detection of *Mycobacterium tuberculosis* Direct Test inhibitors in clinical specimens. *Diagn Microbiol Infect Dis* 2004;50:109-11
369. Abu-Amro KK. Potential for the use of Polymerase Chain Reaction (PCR) in the detection and identification of *Mycobacterium tuberculosis* complex in sputum samples. *Mol Biol Today* 2002; 3(2): 39-42
370. Al Zahrani K, Al Jahdali H, Poirier L, Rene P, Gennaro ML, Menzies D. Accuracy and utility of commercially available amplification and serologic tests for the diagnosis of minimal pulmonary tuberculosis. *Am J Respir Crit Care Med* 2000;162: 1323-29
371. Al Zahrani K, Al Jahdali H, Poirier L, Rene P, Menzies D. Yield of smear, culture and amplification tests from repeated sputum induction for the diagnosis of pulmonary tuberculosis. *Int J Tuberc Lung Dis* 2001; 5 (9) : 855-860
372. Boddingtonhaus B, Wichelhaus TA, Brade V, Bittner T. Removal of PCR inhibitors by silica membranes: evaluating the Amplicor *Mycobacterium tuberculosis* kit. *J Clin Microbiol* 2001; 39(10): 3750-2
373. Bodmer T, Gurtner A, Scholkmann M, Matter L. Evaluation of the COBAS AMPLICOR MTB system. *J Clin Microbiol* 1997; 35(6): 1604-05
374. Brown TJ, Power EG, French GL. Evaluation of three commercial detection systems for *Mycobacterium tuberculosis* where clinical diagnosis is difficult. *J Clin Pathol* 1999; 52(3): 193-7
375. Burggraf S, Reischl U, Malik N, Bollwein M, Naumann L, Olgemoller B. Comparison of an internally controlled, large-volume LightCycler assay for detection of *Mycobacterium tuberculosis* in clinical samples with the COBAS AMPLICOR assay. *J Clin Microbiol* 2005; 43(4): 1564-9
376. Catanzaro A, Perry S, Clarridge JE, Dunbar S, Goodnight-White S, LoBue PA, Peter C, Pfyffer GE, Sierra MF, Weber R, Woods G, Mathews G, Jonas V, Smith K, Della-Latta P. The role of clinical suspicion in evaluating a new diagnostic test for active tuberculosis: results of a multicenter prospective trial. *JAMA* 2000; 283(5): 639-45
377. Chin DP, Yajko DM, Hadley WK, Sanders CA, Nassos PS, Madej JJ, Hopewell PC. Clinical utility of a commercial test based on the polymerase chain reaction for detecting *Mycobacterium tuberculosis* in respiratory specimens. *Am J Respir Crit Care Med* 1995; 151(6): 1872-77

378. Della-Latta P, Whittier S. Comprehensive evaluation of performance, laboratory application, and clinical usefulness of two direct amplification technologies for the detection of *Mycobacterium tuberculosis* complex. *Am J Clin Pathol* 1998; 110(3): 301-10
379. Drosten C, Panning M, Kramme S. Detection of *Mycobacterium tuberculosis* by real-time PCR using pan-mycobacterial primers and a pair of fluorescence resonance energy transfer probes specific for the *M. tuberculosis* complex. *Clin Chem* 2003; 49(10): 1659-61
380. Ehlers S, Pirmann M, Zaki W, Hahn H. Evaluation of a commercial rRNA target amplification assay for detection of *Mycobacterium tuberculosis* complex in respiratory specimens. *Eur J Clin Microbiol Infect Dis* 1994; 13(10): 827-9
381. Fadda G, Ardito F, Sanguinetti M, Posteraro B, Ortona L, Chezzi C, Polonelli L, Dettori G, Conti S, Fanti F, Galli C. Evaluation of the Abbott LCx *Mycobacterium tuberculosis* assay in comparison with culture methods in selected Italian patients. *New Microbiol* 1998; 21(2): 97-103
382. Garrino MG, Glupczynski Y, Degraux J, Nized H, Delmee M. Evaluation of the Abbott LCx *Mycobacterium tuberculosis* assay for direct detection of *Mycobacterium tuberculosis* complex in human samples. *J Clin Microbiol* 1999; 37(1): 229-32
383. Goessens WH, de Man P, Koeleman JG, Luijendijk A, te Witt R, Endtz HP, van Belkum A. Comparison of the COBAS AMPLICOR MTB and BDProbeTec ET assays for detection of *Mycobacterium tuberculosis* in respiratory specimens. *J Clin Microbiol* 2005; 43(6): 2563-6
384. Huang TS, Huang WK, Lee SS, Tu HZ, Chang SH, Liu YC. Rapid detection of pulmonary tuberculosis using the BDProbeTEC ET *Mycobacterium tuberculosis* Complex Direct Detection Assay (DTB). *Diagn Microbiol Infect Dis* 2003; 46(1): 29-33
385. Huang TS, Liu YC, Lin HH, Huang WK, Cheng DL. Comparison of the Roche AMPLICOR MYCOBACTERIUM assay and Digene SHARP Signal System with in-house PCR and culture for detection of *Mycobacterium tuberculosis* in respiratory specimens. *J Clin Microbiol* 1996; 34(12): 3092-96
386. Ichiyama S, Ito Y, Sugiura F, Iinuma Y, Yamori S, Shimojima M, Hasegawa Y, Shimokata K, Nakashima N. Diagnostic value of the strand displacement amplification method compared to those of Roche Amplicor PCR and culture for detecting mycobacteria in sputum samples. *J Clin Microbiol* 1997; 35(12): 3082-85
387. Jackson KM, Edwards RM, Bowden DS, Leslie DE. Evaluation of the Roche Amplicor polymerase chain reaction system for detection of *Mycobacterium tuberculosis* complex in specimens. *Pathology* 1996; 28(1): 65-7
388. Jungkind D, Drenzo S, Beavis KG, Silverman NS. Evaluation of automated COBAS AMPLICOR PCR system for detection of several infectious agents and its impact on laboratory management. *J Clin Microbiol* 1996; 34(11): 2778-83
389. Kambashi B, Mbulo G, McNerney R, Tembwe R, Kambashi A, Tuhon V, Godfrey-Faussett P, Zambart. Utility of nucleic acid amplification technique for the diagnosis of pulmonary tuberculosis in Sub-Saharan Africa. *Int J Tuberc Lung Dis* 2001; 5(4): 364-69
390. Kaul KL. Molecular detection of *Mycobacterium tuberculosis*: impact on patient care. *Clin Chem* 2001; 47(8): 1553-8
391. Kerleguer A, Koeck JL, Fabre M, Gerome P, Teyssou R, Herve V. Use of equivocal zone in interpretation of results of the amplified mycobacterium tuberculosis direct test for diagnosis of tuberculosis. *J Clin Microbiol* 2003; 41(4): 1783-4
392. Kivihya-Ndugga L, van Cleeff M, Juma E, Kimwomi J, Githui W, Oskam L, Schuitema A, van Soolingen D, Nganga L, Kibuga D, Odhiambo J, Klatser P. Comparison of PCR with the routine procedure for diagnosis of tuberculosis in a population with high prevalences of tuberculosis and human immunodeficiency virus. *J Clin Microbiol* 2004; 42(3):1012-5
393. Middleton AM, Cullinan P, Wilson R, Kerr JR, Chadwick MV. Interpreting the results of the amplified *Mycobacterium tuberculosis* direct test for detection of *M. tuberculosis* rRNA. *J Clin Microbiol* 2003; 41(6): 2741-3
394. Moore DF, Guzman JA, Mikhail LT. Reduction in turnaround time for laboratory diagnosis of pulmonary tuberculosis by routine use of a nucleic acid amplification test. *Diagn Microbiol Infect Dis* 2005; 52(3): 247-54
395. O'Connor TM, Sheehan S, Cryan B, Brennan N, Bredin CP. The ligase chain reaction as a primary screening tool for the detection of culture positive tuberculosis. *Thorax* 2000; 55(11): 955-57

396. Rajalahti I, Vuorinen P, Nieminen MM, Miettinen A. Detection of Mycobacterium tuberculosis complex in sputum specimens by the automated Roche Cobas Amplicor Mycobacterium tuberculosis test. *J Clin Microbiol* 1998; 36(4): 975-78
397. Rantakokko-Jalava K, Marjamäki M, Marttila H, Mäkelä L, Valtonen V, Viljanen MK. LCx Mycobacterium tuberculosis assay is valuable with respiratory specimens, but provides little help in the diagnosis of extrapulmonary tuberculosis. *Ann Med* 2001; 33(1): 55-62
398. Ribeiro FK, Dettoni V, Peres RL, Vinhas SA, Co TR, Dietze R, Palaci M. Evaluation of a commercial test based on ligase chain reaction for direct detection of Mycobacterium tuberculosis in respiratory specimens. *Rev Soc Bras Med Trop* 2004; 37(6): 431-5
399. Ruiz-Serrano MJ, Albadalejo J, Martinez-Sanchez L, Bouza E. LCx: a diagnostic alternative for the early detection of Mycobacterium tuberculosis complex. *Diagn Microbiol Infect Dis* 1998; 32(4): 259-64
400. Salajka F, Mezensky L, Pokorny A. Commercial polymerase chain reaction test (Amplicor set) in the diagnosis of smear-negative pulmonary tuberculosis from sputum and bronchoalveolar lavage. *Monaldi Arch Chest Dis* 2000; 55(1): 9-12
401. Schirm J, Oostendorp LAB, Mulder JG. Comparison of Amplicor, in-house PCR and conventional culture for detection of Mycobacterium tuberculosis in clinical samples. *J Clin Microbiol* 1995; 33: 3221-24
402. Sloutsky A, Han LL, Werner BG. Practical strategies for performance optimization of the enhanced gen-probe amplified mycobacterium tuberculosis direct test. *J Clin Microbiol* 2004; 42(4): 1547-51
403. Stauffer F, Mutschlechner R, Hasenberger P, Stadlbauer S, Schinko H. Detection of Mycobacterium tuberculosis complex in clinical specimens by a commercial polymerase chain reaction kit. *Eur J Clin Microbiol Infect Dis* 1995; 14(12): 1046-51
404. Tonjum T, Klintz L, Bergan T, Baann J, Furuberg G, Cristea M, Petrini B, Hoffner S. Direct detection of Mycobacterium tuberculosis in respiratory samples from patients in Scandinavia by polymerase chain reaction. *Clin Microbiol Infect* 1996; 2(2): 127-31
405. Tortoli E, Lavinia F, Simonetti MT. Evaluation of a commercial ligase chain reaction kit (Abbott LCx) for direct detection of Mycobacterium tuberculosis in pulmonary and extrapulmonary specimens. *J Clin Microbiol* 1997; 35(9): 2424-26
406. Tortoli E, Tronci M, Tosi CP, Galli C, Lavinia F, Natili S, Goglio A. Multicentre evaluation of two commercial amplification kits (Amplicor, Roche and LCx, Abbott) for direct detection of Mycobacterium tuberculosis in pulmonary and extrapulmonary specimens. *Diagn Microbiol Infect Dis* 1999; 33: 173-79
407. Yam WC, Tam CM, Leung CC, Tong HL, Chan KH, Leung ETY, Wong KC, Yew WW, Seto WH, Yuen KY, Ho PL. Direct detection of rifampin resistance Mycobacterium tuberculosis in respiratory by PCR-DNA sequencing. *J Clin Microbiol* 2004; 42: 4438-43
408. D'Amato RF, Miller A. Rapid diagnosis of pulmonary tuberculosis using Roche AMPLICOR Mycobacterium tuberculosis PCR test. *Methods Mol Biol*. 1998; 92: 203-14
409. Hengstler M, Klavehn P, Glockner G, Fahr AM. Evaluation of the Amplicor(TM) Mycobacterium tuberculosis amplification and detection kit in a clinical laboratory: Results and experiences. *Klinisches Labor* 1996; 42(5): 387-393
410. Iinuma Y, Ichiyama S, Yamori S, Oohama J, Takagi N, Hasegawa Y, Shimokata K, Nakashima N. Diagnostic value of the Amplicor PCR assay for initial diagnosis and assessment of treatment response for pulmonary tuberculosis. *Microbiol Immunol* 1998; 42: 281-87
411. Cohen RA, Muzaffar S, Schwartz D, Bashir S, Luke S, McGartland LP, Kaul K. Diagnosis of pulmonary tuberculosis using PCR assays on sputum collected within 24 hours of hospital admission. *Am J Respir Crit Care Med* 1998; 157(1): 156-61
412. Kwiatkowska S, Marczak J, Zieba M, Nowak D. Clinical utility of a commercial ligase chain reaction kit for the diagnosis of smear-negative pulmonary tuberculosis. *Int J Tuberc Lung Dis* 1999; 3(5): 421-5
413. Lim TK, Gough A, Chin NK, Kumarasinghe G. Relationship between estimated pretest probability and accuracy of automated Mycobacterium tuberculosis assay in smear-negative pulmonary tuberculosis. *Chest* 2000; 118(3): 641-47
414. Lim TK, Mukhopadhyay A, Gough A, Khoo KL, Khoo SM, Lee KH, Kumarasinghe G. Role of clinical judgment in the application of a nucleic acid amplification test for the rapid diagnosis of pulmonary tuberculosis. *Chest* 2003; 124(3): 902-8

415. Lim TK, Zhu D, Gough A, Lee KH, Kumarasinghe G. What is the optimal approach for using a direct amplification test in the routine diagnosis of pulmonary tuberculosis? A preliminary assessment. *Respirology* 2002; 7(4): 351-7
416. Van den Wijngaert S, Dediste A, VanLaethem Y, Gerard M, Vandenberg O, Zissis G. Critical use of nucleic acid amplification techniques to test for *Mycobacterium tuberculosis* in respiratory tract samples. *J Clin Microbiol* 2004; 42(2):837-8
417. Alcalá L, Ruiz-Serrano MJ, Hernangomez S, Marin M, de Viedma DG, San Juan R, Bouza E. Evaluation of the upgraded amplified *Mycobacterium tuberculosis* direct test (Gen-Probe) for direct detection of *Mycobacterium tuberculosis* in respiratory and non-respiratory specimens. *Diagn Microbiol Infect Dis* 2001; 41(1-2): 51-6
418. Ausina V, Gamboa F, Gazapo E, Manterola JM, Lonca J, Matas L, Manzano JR, Rodrigo C, Cardona PJ, Padilla E. Evaluation of the semiautomated AbbotLCX *Mycobacterium tuberculosis* assay for direct detection of *Mycobacterium tuberculosis* in respiratory specimens. *J Clin Microbiol* 1997; 35: 1996-2002
419. Barrett A, Magee JG, Freeman R. An evaluation of the BDProbeTec ET system for the direct detection of *Mycobacterium tuberculosis* in respiratory samples. *J Med Microbiol* 2002; 51(10): 895-8
420. Beavis KG, Lichty MB, Jungking DL, Giger O. Evaluation of AMPLICOR PCR for direct detection of *Mycobacterium tuberculosis* from sputum specimens. *J Clin Microbiol* 1995; 33:2582-86
421. Bennedsen J, Thomsen VO, Pfyffer GE, Funke G, Feldmann K, Beneke A, Jenkins PA, Hegglinbothom M, Fahr A, Hengstler M, Cleator G, Klapper P, Wilkins EG. Utility of PCR in diagnosing pulmonary tuberculosis. *J Clin Microbiol* 1996; 34(6): 1407-11
422. Bergmann JS, Keating WE, Woods GL. Clinical evaluation of the BDProbeTec ET system for rapid detection of *Mycobacterium tuberculosis*. *J Clin Microbiol* 2000; 38(2): 863-5
423. Bergmann JS, Woods GL. Clinical evaluation of the Roche AMPLICOR PCR *Mycobacterium tuberculosis* test for detection of *M. tuberculosis* in respiratory specimens. *J Clin Microbiol* 1996; 34(5): 1083-85
424. Bergmann JS, Yuoh G, Fish G, Woods GL. Clinical evaluation of the enhanced Gen-Probe Amplified *Mycobacterium tuberculosis* Direct Test for rapid diagnosis of tuberculosis in prison inmates. *J Clin Microbiol* 1999; 37: 1419-25
425. Bodmer T, Mockl E, Muhlemann K, Matter L. Improved performance of Gen-Probe Amplified *Mycobacterium Tuberculosis* Direct Test when 500 instead of 50 microliters of decontaminated sediment is used. *J Clin Microbiol* 1996; 34(1): 222-23
426. Bogard M, Vincelette J, Antinozzi R, Alonso R, Fenner T, Schirm J, Aubert D, Gaudreau C, Sala E, Ruiz-Serrano MJ, Petersen H, Oostendorp LA, Burkardt H. Multicenter study of a commercial, automated polymerase chain reaction system for the rapid detection of *Mycobacterium tuberculosis* in respiratory specimens in routine clinical practice. *Eur J Clin Microbiol Infect Dis* 2001; 20(10): 724-31
427. Cartuyvels R, De Ridder C, Jonckheere S, Verbist L, Van Eldere J. Prospective clinical evaluation of Amplicor *Mycobacterium tuberculosis* PCR test as a screening method in a low-prevalence population. *J Clin Microbiol* 1996; 34(8): 2001-3
428. Chedore P, Jamieson FB. Routine use of the Gen-Probe MTD2 amplification test for detection of *Mycobacterium tuberculosis* in clinical specimens in a large public health mycobacteriology laboratory. *Diagn Microbiol Infect Dis* 1999; 35(3): 185-91
429. Cleary TJ, Roudel G, Casillas O, Miller N. Rapid and specific detection of *Mycobacterium tuberculosis* by using the Smart Cycler instrument and a specific fluorogenic probe. *J Clin Microbiol* 2003; 41(10): 4783-6
430. Coll P, Garrigo M, Moreno C, Marti N. Routine use of Gen-Probe Amplified *Mycobacterium Tuberculosis* Direct (MTD) test for detection of *Mycobacterium tuberculosis* with smear-positive and smear-negative specimens. *Int J Tuberc Lung Dis*. 2003; 7(9): 886-91
431. Dalovisio JR, Montenegro-James S, Kemmerly SA, Genre CF, Chambers R, Greer D, Pankey GA, Failla DM, Haydel KG, Hutchinson L, Lindley MF, Nunez BM, Praba A, Eisenach KD, Cooper ES. Comparison of the Amplified *M.tuberculosis* (MTB)direct test, Amplicor MTB PCR and IS6110-PCR for detection of MTB in respiratory specimens. *Clin Infect Dis* 1996; 23: 1099-106

432. D'Amato RF, Wallman AA, Hochstein LH, Colaninno PM, Scardamaglia M, Ardila E, Ghouri M, Kim K, Patel RC, Miller A. Rapid diagnosis of pulmonary tuberculosis by using Roche AMPLICOR Mycobacterium tuberculosis PCR test. *J Clin Microbiol* 1995; 33(7): 1832-34
433. De La Calle IJ, De La Calle MAJ, Rodriguez-Iglesias M. Evaluation of the BDProbeTec et system as screening tool in the direct detection of mycobacterium tuberculosis complex in respiratory specimens. *Diagn Microbiol Infect Dis* 2003; 47(4): 573-8
434. Denis O, Devaster JM, Vandenberg O, Vanachter H, Lafontaine T, Lin C, Butzler JP Evaluation of ligase chain reaction for direct detection of Mycobacterium tuberculosis in respiratory specimens. *Zentralbl Bakteriell* 1998; 288(1): 59-65
435. Dilworth JP, Goyal M, Young DB, Shaw RJ. Comparison of polymerase chain reaction for IS6110 and Amplicor in the diagnosis of tuberculosis. *Thorax* 1996; 51(3): 320-22
436. Gallina M, Troupioti P, Rocco G, Sensalari G, Libanori E. Predicting culture results for Mycobacterium tuberculosis complex. Amplified mycobacterium tuberculosis direct test and acid-fast bacilli microscopy. *Chest* 2000; 118(1): 28-32
437. Gamboa F, Fernandez G, Padilla E, Manterola JM, Lonca J, Cardona PJ, Matas L, Ausina V. Comparative evaluation of initial and new versions of the Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test for direct detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens. *J Clin Microbiol* 1998; 36(3): 684-89
438. Gamboa F, Manterola JM, Lonca J, Matas L, Cardona PJ, Padilla E, Vinado B, Dominguez J, Hernandez A, Ausina V. Comparative evaluation of two commercial assays for direct detection of Mycobacterium tuberculosis in respiratory specimens. *Eur J Clin Microbiol Infect Dis* 1998; 17(3): 151-57
439. Gurkan O, Acican T, Gulbay B. Evaluation of an amplified Mycobacterium tuberculosis direct test in clinical specimens. *Int J Tuberc Lung Dis* 2002; 6(6): 538-41
440. Ichiyama S, Iinuma Y, Tawada Y, Yamori S, Hasegawa Y, Shimokata K, Nakashima N. Evaluation of Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test and Roche PCR-microwell plate hybridization method (AMPLICOR MYCOBACTERIUM) for direct detection of mycobacteria. *J Clin Microbiol* 1996; 34(1): 130-33
441. Iinuma Y, Senda K, Fujihara N, Saito T, Takakura S, Shimojima M, Kudo T, Ichiyama S. Comparison of the BDProbeTec ET system with the Cobas Amplicor PCR for direct detection of Mycobacterium tuberculosis in respiratory samples. *Eur J Clin Microbiol Infect Dis* 2003; 22(6): 368-71
442. Iwamoto T, Sonobe T, Hayashi K. Loop-mediated isothermal amplification for direct detection of Mycobacterium tuberculosis complex, M. avium, and M. intracellulare in sputum samples. *J Clin Microbiol* 2003; 41(6): 2616-22
443. Jan IS, Hsueh PR, Teng LJ, Lee LN, Yang PC, Luh KT. Evaluation of an automatic polymerase chain reaction assay for identification of Mycobacterium tuberculosis in respiratory specimens. *J Formos Med Assoc* 1998; 97(3): 204-9
444. Johansen IS, Thomsen VO, Johansen A, Andersen P, Lundgren B. Evaluation of a new commercial assay for diagnosis of pulmonary and nonpulmonary tuberculosis. *Eur J Clin Microbiol Infect Dis* 2002; 21(6): 455-60
445. Jonsson B, Ridell M. The Cobas Amplicor MTB test for detection of Mycobacterium tuberculosis complex from respiratory and non-respiratory clinical specimens. *Scand J Infect Dis* 2003; 35(6-7): 372-7
446. Kearns AM, Freeman R, Steward M, Magee JG. A rapid polymerase chain reaction technique for detecting M tuberculosis in a variety of clinical specimens. *J Clin Pathol* 1998; 51(12): 922-24
447. Kim SY, Park YJ, Kang SJ, Kim BK, Kang CS. Comparison of the BDProbeTec ET system with the roche COBAS AMPLICOR System for detection of Mycobacterium tuberculosis complex in the respiratory and pleural fluid specimens. *Diagn Microbiol Infect Dis* 2004; 49(1): 13-8
448. Lebrun L, Mathieu D, Saulnier C, Nordmann P. Limits of commercial molecular tests for diagnosis of pulmonary tuberculosis. *Eur Respir J* 1997; 10(8): 1874-76
449. Lemaitre N, Armand S, Vachee A, Capilliez O, Dumoulin C, Courcol RJ. Comparison of real-time PCR method and the Gen-Probe Amplified Mycobacterium tuberculosis direct test for detection of Mycobacterium tuberculosis in pulmonary and nonpulmonary specimens. *J Clin Microbiol* 2004; 42(9): 4307-9
450. Levidiotou S, Vrioni G, Galanakis E, Gesouli E, Pappa C, Stefanou D. Four-year experience of use of the Cobas Amplicor system for rapid detection of Mycobacterium tuberculosis complex



- in respiratory and nonrespiratory specimens in Greece. *Eur J Clin Microbiol Infect Dis* 2003; 22(6): 349-56
451. Liu D, Jones SL, Baird R, Pedersen J. Use of Roche Amplicor and multiplex PCR for diagnosis of human mycobacterial infections. *Opportunistic Pathogens* 1997; 9(1): 51-55
  452. Lumb R, Davies K, Dawson D, Gibb R, Gottlieb T, Kershaw C, Kociuba K, Nimmo G, Sangster N, Worthington M, Bastian I. Multicenter evaluation of the Abbott LCx Mycobacterium tuberculosis ligase chain reaction assay. *J Clin Microbiol* 1999; 37(10): 3102-07
  453. Maugein J, Fourche J, Vacher S, Grimond C, Bebear C. Evaluation of the BDProbeTec ET DTB assay(1) for direct detection of Mycobacterium tuberculosis complex from clinical samples. *Diagn Microbiol Infect Dis* 2002; 44(2): 151-5
  454. Mazzarelli G, Rindi L, Piccoli P, Scarparo C, Garzelli C, Tortoli E. Evaluation of the BDProbeTec ET system for direct detection of Mycobacterium tuberculosis in pulmonary and extrapulmonary samples: a multicenter study. *J Clin Microbiol* 2003; 41(4): 1779-82
  455. McHugh TD, Pope CF, Ling CL, Patel S, Billington OJ, Gosling RD, Lipman MC, Gillespie SH. Prospective evaluation of BDProbeTec strand displacement amplification (SDA) system for diagnosis of tuberculosis in non-respiratory and respiratory samples. *J Med Microbiol* 2004; 53: 1215-9
  456. Miller N, Cleary T, Kraus G, Young AK, Spruill G, Hnatyszyn HJ. Rapid and specific detection of Mycobacterium tuberculosis from acid-fast bacillus smear-positive respiratory specimens and BacT/ALERT MP culture bottles by using fluorogenic probes and real-time PCR. *J Clin Microbiol* 2002; 40(11): 4143-7
  457. Moore DF, Curry JL. Detection and identification of Mycobacterium tuberculosis directly from sputum sediments by AMPLICOR PCR. *J Clin Microbiol* 1995; 33: 2686-91
  458. Moore G, Curry JL. Detection and identification of Mycobacterium tuberculosis directly from sputum sediments by ligase chain reaction. *J Clin Microbiol* 1998; 36: 1028-31
  459. O'Sullivan CE, Miller DR, Schneider PS, Roberts GD. Evaluation of Gen-Probe amplified mycobacterium tuberculosis direct test by using respiratory and nonrespiratory specimens in a tertiary care center laboratory. *J Clin Microbiol* 2002; 40(5): 1723-7
  460. Piersimoni C, Callegaro A, Nista D, Bornigia S, De Conti F, Santini G, De Sio G. Comparative evaluation of two commercial amplification assays for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. *J Clin Microbiol* 1997; 35(1): 193-6
  461. Piersimoni C, Callegaro A, Scarparo C, Penati V, Nista D, Bornigia S, Lacchini C, Scagnelli M, Santini G, De Sio G. Comparative evaluation of the new Gen-Probe Mycobacterium tuberculosis Amplified Direct Test and the semiautomated Abbott LCx Mycobacterium tuberculosis assay for direct detection of Mycobacterium tuberculosis complex in respiratory and extrapulmonary specimens. *J Clin Microbiol* 1998; 36: 3601-04
  462. Piersimoni C, Scarparo C, Piccoli P, Rigon A, Ruggiero G, Nista D, Bornigia S. Performance assessment of two commercial amplification assays for direct detection of Mycobacterium tuberculosis complex from respiratory and extrapulmonary specimens. *J Clin Microbiol* 2002; 40(11): 4138-42
  463. Reischl U, Lehn N, Wolf H, Naumann L. Clinical evaluation of the automated COBAS AMPLICOR MTB assay for testing respiratory and nonrespiratory specimens. *J Clin Microbiol* 1998; 36: 2853-60
  464. Rohner P, Jahn EI, Ninet B, Ionati C, Weber R, Auckenthaler R, Pfyffer GE. Rapid diagnosis of pulmonary tuberculosis with the LCx Mycobacterium tuberculosis assay and comparison with conventional diagnostic techniques. *J Clin Microbiol* 1998; 36(10): 3046-47
  465. Rusch-Gerdes S, Richter E. Clinical evaluation of the semiautomated BDProbeTec ET System for the detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens. *Diagn Microbiol Infect Dis* 2004; 48(4):265-70
  466. Scarparo C, Piccoli P, Rigon A, Ruggiero G, Scagnelli M, Piersimoni C. Comparison of enhanced Mycobacterium tuberculosis amplified direct test with Cobas Amplicor Mycobacterium tuberculosis assay for direct detection of Mycobacterium tuberculosis complex in respiratory and extrapulmonary specimens. *J Clin Microbiol* 2000; 38: 1559-62
  467. Smith MB, Bergmann JS, Harris SL, Woods GL. Evaluation of Roche Amplicor MTB assay for the detection of mycobacterium tuberculosis in sputum specimens from prison inmates. *Diagn Microbiol Infect Dis* 1997; 27: 113-16

468. Smith MB, Bergmann JS, Onoroto M, Mathews G, Woods GL. Evaluation of the enhanced amplified Mycobacterium tuberculosis direct test for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. *Arch Pathol Lab Med* 1999; 123(11): 1101-3
469. Soini H, Agha SA, El-Fiky A, Viljanen MK. Comparison of amplicor and 32-kilodalton PCR for detection of Mycobacterium tuberculosis from sputum specimens. *J Clin Microbiol* 1996; 34(7): 1829-30
470. Tevere VJ, Hewitt PL, Dare A, Hocknell P, Keen A, Spadaro JP, Young KK. Detection of Mycobacterium tuberculosis by PCR amplification with pan-Mycobacterium primers and hybridization to an M. tuberculosis-specific probe. *J Clin Microbiol* 1996; 34(4): 918-23
471. Viinanen AH, Soini H, Marjamaki M, Liippo K, Viljanen MK. Ligase chain reaction assay is clinically useful in the discrimination of smear-positive pulmonary tuberculosis from atypical mycobacterioses. *Ann Med* 2000; 32(4): 279-83
472. Viveiros M, Pinheiro S, Moreira P, Pacheco T, Brum L. Evaluation of a commercial ligase chain reaction assay for the diagnosis of pulmonary and extra-pulmonary tuberculosis. *Int J Tuberc Lung Dis* 1999; 3(6): 508-14
473. Vuorinen P, Miettinen A, Vuento R, Hallstrom O. Direct detection of Mycobacterium tuberculosis complex in respiratory specimens by Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test and Roche Amplicor Mycobacterium Tuberculosis Test. *J Clin Microbiol* 1995; 33(7): 1856-59
474. Wang JY, Lee LN, Chou CS, Huang CY, Wang SK, Lai HC, Hsueh PR, Luh KT. Performance assessment of a nested-PCR assay (the rapid BAP-MTB) and the BDProbeTec ET system for detection of Mycobacterium tuberculosis in clinical specimens. *J Clin Microbiol* 2004; 43 (10): 4599-603
475. Wang SX, Tay L. Evaluation of three nucleic acid amplification methods for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. *J Clin Microbiol* 1999; 37(6): 1932-34
476. Yam WC, Yuen KY, Seto WH. Direct detection of Mycobacterium tuberculosis in respiratory specimens using an automated DNA amplification assay and a single tube nested polymerase chain reaction (PCR). *Clin Chem Lab Med* 1998; 36(8): 597-9
477. Yee YC, Gough A, Kumarasinghe G, Lim TK. The pattern of utilisation and accuracy of a commercial nucleic acid amplification test for the rapid diagnosis of Mycobacterium tuberculosis in routine clinical practice. *Singapore Med J* 2002; 43(8): 415-20
478. Yuen KY, Yam WC, Wong LP, Seto WH. Comparison of two automated DNA amplification systems with a manual one-tube nested PCR assay for diagnosis of pulmonary tuberculosis. *J Clin Microbiol* 1997; 35(6): 1385-89
479. Zolnir-Dovc M, Poljak M, Seme K, Rus A, Avsic-Zupanc T. Evaluation of two commercial amplification assays for detection of Mycobacterium tuberculosis complex in respiratory specimens. *Infection* 1995; 23(4): 216-21
480. Dickersin K. The existence of publication bias and risk factors for its occurrence. *JAMA* 1990; 263: 1385-9
481. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test publication bias. *Biometrics* 1994; 50: 1088-101
482. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997; 315: 629-34